CN107619407B - Bis- target spot inhibitor of HDAC and VEGFR based on pazopanib structure and its preparation method and application - Google Patents
Bis- target spot inhibitor of HDAC and VEGFR based on pazopanib structure and its preparation method and application Download PDFInfo
- Publication number
- CN107619407B CN107619407B CN201710677980.2A CN201710677980A CN107619407B CN 107619407 B CN107619407 B CN 107619407B CN 201710677980 A CN201710677980 A CN 201710677980A CN 107619407 B CN107619407 B CN 107619407B
- Authority
- CN
- China
- Prior art keywords
- amino
- methyl
- base
- room temperature
- acid
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
- 238000002360 preparation method Methods 0.000 title claims abstract description 81
- CUIHSIWYWATEQL-UHFFFAOYSA-N pazopanib Chemical group C1=CC2=C(C)N(C)N=C2C=C1N(C)C(N=1)=CC=NC=1NC1=CC=C(C)C(S(N)(=O)=O)=C1 CUIHSIWYWATEQL-UHFFFAOYSA-N 0.000 title claims abstract description 35
- 102100033177 Vascular endothelial growth factor receptor 2 Human genes 0.000 title claims abstract description 24
- 108091008605 VEGF receptors Proteins 0.000 title claims abstract description 19
- 239000003112 inhibitor Substances 0.000 title claims abstract description 17
- 108090000353 Histone deacetylase Proteins 0.000 title claims abstract description 11
- 102000003964 Histone deacetylase Human genes 0.000 title claims abstract description 11
- 150000001875 compounds Chemical class 0.000 claims abstract description 51
- 206010028980 Neoplasm Diseases 0.000 claims abstract description 30
- 239000003814 drug Substances 0.000 claims abstract description 28
- 229940079593 drug Drugs 0.000 claims abstract description 23
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 claims description 189
- -1 Methylurea tetrafluoro boric acid Chemical compound 0.000 claims description 133
- 238000006243 chemical reaction Methods 0.000 claims description 97
- ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 claims description 93
- ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 claims description 66
- KWYUFKZDYYNOTN-UHFFFAOYSA-M Potassium hydroxide Chemical compound [OH-].[K+] KWYUFKZDYYNOTN-UHFFFAOYSA-M 0.000 claims description 63
- 150000002148 esters Chemical class 0.000 claims description 51
- WTDHULULXKLSOZ-UHFFFAOYSA-N Hydroxylamine hydrochloride Chemical compound Cl.ON WTDHULULXKLSOZ-UHFFFAOYSA-N 0.000 claims description 50
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 claims description 48
- 230000002829 reductive effect Effects 0.000 claims description 43
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 claims description 42
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims description 39
- KDLHZDBZIXYQEI-UHFFFAOYSA-N Palladium Chemical compound [Pd] KDLHZDBZIXYQEI-UHFFFAOYSA-N 0.000 claims description 36
- 239000002253 acid Substances 0.000 claims description 28
- WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 claims description 20
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 claims description 18
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 claims description 18
- 150000004702 methyl esters Chemical class 0.000 claims description 17
- BWHMMNNQKKPAPP-UHFFFAOYSA-L potassium carbonate Chemical compound [K+].[K+].[O-]C([O-])=O BWHMMNNQKKPAPP-UHFFFAOYSA-L 0.000 claims description 16
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 claims description 14
- 229910052757 nitrogen Inorganic materials 0.000 claims description 14
- 150000001408 amides Chemical class 0.000 claims description 13
- 239000012467 final product Substances 0.000 claims description 13
- 239000001257 hydrogen Substances 0.000 claims description 13
- 229910052739 hydrogen Inorganic materials 0.000 claims description 13
- 238000005915 ammonolysis reaction Methods 0.000 claims description 12
- 239000003153 chemical reaction reagent Substances 0.000 claims description 12
- 238000010534 nucleophilic substitution reaction Methods 0.000 claims description 12
- 238000010992 reflux Methods 0.000 claims description 12
- 239000007858 starting material Substances 0.000 claims description 12
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 claims description 11
- YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 claims description 10
- GEYOCULIXLDCMW-UHFFFAOYSA-N 1,2-phenylenediamine Chemical compound NC1=CC=CC=C1N GEYOCULIXLDCMW-UHFFFAOYSA-N 0.000 claims description 9
- ALYNCZNDIQEVRV-UHFFFAOYSA-N 4-aminobenzoic acid Chemical compound NC1=CC=C(C(O)=O)C=C1 ALYNCZNDIQEVRV-UHFFFAOYSA-N 0.000 claims description 8
- 229910000027 potassium carbonate Inorganic materials 0.000 claims description 8
- FYSNRJHAOHDILO-UHFFFAOYSA-N thionyl chloride Chemical compound ClS(Cl)=O FYSNRJHAOHDILO-UHFFFAOYSA-N 0.000 claims description 8
- 239000004327 boric acid Substances 0.000 claims description 7
- 238000000034 method Methods 0.000 claims description 7
- WKBOTKDWSSQWDR-UHFFFAOYSA-N Bromine atom Chemical compound [Br] WKBOTKDWSSQWDR-UHFFFAOYSA-N 0.000 claims description 6
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 6
- PAYRUJLWNCNPSJ-UHFFFAOYSA-N N-phenyl amine Natural products NC1=CC=CC=C1 PAYRUJLWNCNPSJ-UHFFFAOYSA-N 0.000 claims description 6
- OKJPEAGHQZHRQV-UHFFFAOYSA-N Triiodomethane Natural products IC(I)I OKJPEAGHQZHRQV-UHFFFAOYSA-N 0.000 claims description 6
- JFBZPFYRPYOZCQ-UHFFFAOYSA-N [Li].[Al] Chemical compound [Li].[Al] JFBZPFYRPYOZCQ-UHFFFAOYSA-N 0.000 claims description 6
- GDTBXPJZTBHREO-UHFFFAOYSA-N bromine Substances BrBr GDTBXPJZTBHREO-UHFFFAOYSA-N 0.000 claims description 6
- 229910052794 bromium Inorganic materials 0.000 claims description 6
- DGXRZJSPDXZJFG-UHFFFAOYSA-N docosanedicarboxylic acid Natural products OC(=O)CCCCCCCCCCCCCCCCCCCCC(O)=O DGXRZJSPDXZJFG-UHFFFAOYSA-N 0.000 claims description 6
- 208000024200 hematopoietic and lymphoid system neoplasm Diseases 0.000 claims description 6
- INQOMBQAUSQDDS-UHFFFAOYSA-N iodomethane Chemical compound IC INQOMBQAUSQDDS-UHFFFAOYSA-N 0.000 claims description 6
- 208000032839 leukemia Diseases 0.000 claims description 6
- VVWPSAPZUZXYCM-UHFFFAOYSA-N nonanedioic acid monomethyl ester Natural products COC(=O)CCCCCCCC(O)=O VVWPSAPZUZXYCM-UHFFFAOYSA-N 0.000 claims description 6
- XUYJLQHKOGNDPB-UHFFFAOYSA-N phosphonoacetic acid Chemical compound OC(=O)CP(O)(O)=O XUYJLQHKOGNDPB-UHFFFAOYSA-N 0.000 claims description 6
- BTTNYQZNBZNDOR-UHFFFAOYSA-N 2,4-dichloropyrimidine Chemical compound ClC1=CC=NC(Cl)=N1 BTTNYQZNBZNDOR-UHFFFAOYSA-N 0.000 claims description 5
- 206010039491 Sarcoma Diseases 0.000 claims description 5
- FJDQFPXHSGXQBY-UHFFFAOYSA-L caesium carbonate Chemical compound [Cs+].[Cs+].[O-]C([O-])=O FJDQFPXHSGXQBY-UHFFFAOYSA-L 0.000 claims description 5
- 229910000024 caesium carbonate Inorganic materials 0.000 claims description 5
- WFQDTOYDVUWQMS-UHFFFAOYSA-N 1-fluoro-4-nitrobenzene Chemical compound [O-][N+](=O)C1=CC=C(F)C=C1 WFQDTOYDVUWQMS-UHFFFAOYSA-N 0.000 claims description 4
- PVNVSSNARYHLRF-UHFFFAOYSA-N 2,3-dimethylindazol-6-amine Chemical compound C1=C(N)C=CC2=C(C)N(C)N=C21 PVNVSSNARYHLRF-UHFFFAOYSA-N 0.000 claims description 4
- BTJIUGUIPKRLHP-UHFFFAOYSA-N 4-nitrophenol Chemical compound OC1=CC=C([N+]([O-])=O)C=C1 BTJIUGUIPKRLHP-UHFFFAOYSA-N 0.000 claims description 4
- 208000021712 Soft tissue sarcoma Diseases 0.000 claims description 4
- TYFQFVWCELRYAO-UHFFFAOYSA-N Suberic acid Natural products OC(=O)CCCCCCC(O)=O TYFQFVWCELRYAO-UHFFFAOYSA-N 0.000 claims description 4
- 229960004050 aminobenzoic acid Drugs 0.000 claims description 4
- UCMIRNVEIXFBKS-UHFFFAOYSA-N beta-alanine Chemical compound NCCC(O)=O UCMIRNVEIXFBKS-UHFFFAOYSA-N 0.000 claims description 4
- 201000011510 cancer Diseases 0.000 claims description 4
- 229960000935 dehydrated alcohol Drugs 0.000 claims description 4
- ULBCJDXDVAJYNI-UHFFFAOYSA-N methyl 5-aminopentanoate Chemical compound COC(=O)CCCCN ULBCJDXDVAJYNI-UHFFFAOYSA-N 0.000 claims description 4
- ZYKOKVARXPKXFW-UHFFFAOYSA-N methyl 8-aminooctanoate Chemical class COC(=O)CCCCCCCN ZYKOKVARXPKXFW-UHFFFAOYSA-N 0.000 claims description 4
- KQSSATDQUYCRGS-UHFFFAOYSA-N methyl glycinate Chemical compound COC(=O)CN KQSSATDQUYCRGS-UHFFFAOYSA-N 0.000 claims description 4
- 235000017557 sodium bicarbonate Nutrition 0.000 claims description 4
- 229910000030 sodium bicarbonate Inorganic materials 0.000 claims description 4
- 208000031261 Acute myeloid leukaemia Diseases 0.000 claims description 3
- 206010006187 Breast cancer Diseases 0.000 claims description 3
- 208000026310 Breast neoplasm Diseases 0.000 claims description 3
- 238000004519 manufacturing process Methods 0.000 claims description 3
- 201000001441 melanoma Diseases 0.000 claims description 3
- 150000003839 salts Chemical class 0.000 claims description 3
- 229910000104 sodium hydride Inorganic materials 0.000 claims description 3
- 238000006467 substitution reaction Methods 0.000 claims description 3
- PBVZQAXFSQKDKK-UHFFFAOYSA-N 3-Methoxy-3-oxopropanoic acid Chemical compound COC(=O)CC(O)=O PBVZQAXFSQKDKK-UHFFFAOYSA-N 0.000 claims description 2
- JDRMYOQETPMYQX-UHFFFAOYSA-M 4-methoxy-4-oxobutanoate Chemical compound COC(=O)CCC([O-])=O JDRMYOQETPMYQX-UHFFFAOYSA-M 0.000 claims description 2
- 208000024893 Acute lymphoblastic leukemia Diseases 0.000 claims description 2
- 208000014697 Acute lymphocytic leukaemia Diseases 0.000 claims description 2
- 208000019838 Blood disease Diseases 0.000 claims description 2
- 208000032027 Essential Thrombocythemia Diseases 0.000 claims description 2
- WLJVNTCWHIRURA-UHFFFAOYSA-N Heptanedioic acid Natural products OC(=O)CCCCCC(O)=O WLJVNTCWHIRURA-UHFFFAOYSA-N 0.000 claims description 2
- 208000002454 Nasopharyngeal Carcinoma Diseases 0.000 claims description 2
- 206010061306 Nasopharyngeal cancer Diseases 0.000 claims description 2
- 208000033755 Neutrophilic Chronic Leukemia Diseases 0.000 claims description 2
- 206010033701 Papillary thyroid cancer Diseases 0.000 claims description 2
- 208000006664 Precursor Cell Lymphoblastic Leukemia-Lymphoma Diseases 0.000 claims description 2
- 206010060862 Prostate cancer Diseases 0.000 claims description 2
- 208000000236 Prostatic Neoplasms Diseases 0.000 claims description 2
- KEAYESYHFKHZAL-UHFFFAOYSA-N Sodium Chemical compound [Na] KEAYESYHFKHZAL-UHFFFAOYSA-N 0.000 claims description 2
- UIIMBOGNXHQVGW-DEQYMQKBSA-M Sodium bicarbonate-14C Chemical compound [Na+].O[14C]([O-])=O UIIMBOGNXHQVGW-DEQYMQKBSA-M 0.000 claims description 2
- 201000008736 Systemic mastocytosis Diseases 0.000 claims description 2
- 238000007171 acid catalysis Methods 0.000 claims description 2
- 208000017733 acquired polycythemia vera Diseases 0.000 claims description 2
- 150000001448 anilines Chemical class 0.000 claims description 2
- JDRMYOQETPMYQX-UHFFFAOYSA-N butanedioic acid monomethyl ester Natural products COC(=O)CCC(O)=O JDRMYOQETPMYQX-UHFFFAOYSA-N 0.000 claims description 2
- 238000006555 catalytic reaction Methods 0.000 claims description 2
- 201000010903 chronic neutrophilic leukemia Diseases 0.000 claims description 2
- 239000003937 drug carrier Substances 0.000 claims description 2
- 208000014951 hematologic disease Diseases 0.000 claims description 2
- 208000018706 hematopoietic system disease Diseases 0.000 claims description 2
- USZLCYNVCCDPLQ-UHFFFAOYSA-N hydron;n-methoxymethanamine;chloride Chemical compound Cl.CNOC USZLCYNVCCDPLQ-UHFFFAOYSA-N 0.000 claims description 2
- 201000007270 liver cancer Diseases 0.000 claims description 2
- 208000014018 liver neoplasm Diseases 0.000 claims description 2
- QAWFLJGZSZIZHO-UHFFFAOYSA-N methyl 4-bromobutanoate Chemical compound COC(=O)CCCBr QAWFLJGZSZIZHO-UHFFFAOYSA-N 0.000 claims description 2
- KYLVAMSNNZMHSX-UHFFFAOYSA-N methyl 6-bromohexanoate Chemical class COC(=O)CCCCCBr KYLVAMSNNZMHSX-UHFFFAOYSA-N 0.000 claims description 2
- 229940102396 methyl bromide Drugs 0.000 claims description 2
- GZUXJHMPEANEGY-UHFFFAOYSA-N methyl bromide Substances BrC GZUXJHMPEANEGY-UHFFFAOYSA-N 0.000 claims description 2
- 206010028537 myelofibrosis Diseases 0.000 claims description 2
- 201000011216 nasopharynx carcinoma Diseases 0.000 claims description 2
- 239000008194 pharmaceutical composition Substances 0.000 claims description 2
- 239000000546 pharmaceutical excipient Substances 0.000 claims description 2
- 208000037244 polycythemia vera Diseases 0.000 claims description 2
- 230000004044 response Effects 0.000 claims description 2
- 239000012312 sodium hydride Substances 0.000 claims description 2
- 208000008732 thymoma Diseases 0.000 claims description 2
- 208000030045 thyroid gland papillary carcinoma Diseases 0.000 claims description 2
- 125000004435 hydrogen atom Chemical class [H]* 0.000 claims 3
- GBMDVOWEEQVZKZ-UHFFFAOYSA-N methanol;hydrate Chemical compound O.OC GBMDVOWEEQVZKZ-UHFFFAOYSA-N 0.000 claims 2
- KVQGGLZHHFGHPU-UHFFFAOYSA-N methyl 4-aminobutanoate Chemical class COC(=O)CCCN KVQGGLZHHFGHPU-UHFFFAOYSA-N 0.000 claims 2
- FSXVZWAWYKMFMX-UHFFFAOYSA-N 5-amino-2-methylbenzoic acid Chemical compound CC1=CC=C(N)C=C1C(O)=O FSXVZWAWYKMFMX-UHFFFAOYSA-N 0.000 claims 1
- 208000032791 BCR-ABL1 positive chronic myelogenous leukemia Diseases 0.000 claims 1
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 claims 1
- 208000010833 Chronic myeloid leukaemia Diseases 0.000 claims 1
- 208000033761 Myelogenous Chronic BCR-ABL Positive Leukemia Diseases 0.000 claims 1
- 230000001154 acute effect Effects 0.000 claims 1
- KGBXLFKZBHKPEV-UHFFFAOYSA-N boric acid Chemical compound OB(O)O KGBXLFKZBHKPEV-UHFFFAOYSA-N 0.000 claims 1
- 229910052792 caesium Inorganic materials 0.000 claims 1
- TVFDJXOCXUVLDH-UHFFFAOYSA-N caesium atom Chemical compound [Cs] TVFDJXOCXUVLDH-UHFFFAOYSA-N 0.000 claims 1
- 229910052799 carbon Inorganic materials 0.000 claims 1
- 208000021668 chronic eosinophilic leukemia Diseases 0.000 claims 1
- 125000002485 formyl group Chemical class [H]C(*)=O 0.000 claims 1
- IBMRTYCHDPMBFN-UHFFFAOYSA-N monomethyl glutaric acid Chemical compound COC(=O)CCCC(O)=O IBMRTYCHDPMBFN-UHFFFAOYSA-N 0.000 claims 1
- 210000003360 nephrocyte Anatomy 0.000 claims 1
- 230000000269 nucleophilic effect Effects 0.000 claims 1
- 229910001950 potassium oxide Inorganic materials 0.000 claims 1
- 208000003476 primary myelofibrosis Diseases 0.000 claims 1
- 210000001525 retina Anatomy 0.000 claims 1
- 230000002265 prevention Effects 0.000 abstract description 2
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 114
- 239000000243 solution Substances 0.000 description 97
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 93
- JMYXMHBOFBYKDR-UHFFFAOYSA-N 2,3-dimethylindazole Chemical compound C1=CC=CC2=C(C)N(C)N=C21 JMYXMHBOFBYKDR-UHFFFAOYSA-N 0.000 description 92
- CZPWVGJYEJSRLH-UHFFFAOYSA-N Pyrimidine Chemical compound C1=CN=CN=C1 CZPWVGJYEJSRLH-UHFFFAOYSA-N 0.000 description 88
- KXDAEFPNCMNJSK-UHFFFAOYSA-N Benzamide Chemical compound NC(=O)C1=CC=CC=C1 KXDAEFPNCMNJSK-UHFFFAOYSA-N 0.000 description 68
- 239000007787 solid Substances 0.000 description 68
- 239000000047 product Substances 0.000 description 53
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 51
- UHOVQNZJYSORNB-UHFFFAOYSA-N Benzene Chemical compound C1=CC=CC=C1 UHOVQNZJYSORNB-UHFFFAOYSA-N 0.000 description 38
- 239000002904 solvent Substances 0.000 description 38
- AVXURJPOCDRRFD-UHFFFAOYSA-N Hydroxylamine Chemical compound ON AVXURJPOCDRRFD-UHFFFAOYSA-N 0.000 description 36
- IAZDPXIOMUYVGZ-WFGJKAKNSA-N Dimethyl sulfoxide Chemical compound [2H]C([2H])([2H])S(=O)C([2H])([2H])[2H] IAZDPXIOMUYVGZ-WFGJKAKNSA-N 0.000 description 34
- 210000004027 cell Anatomy 0.000 description 25
- QGZKDVFQNNGYKY-UHFFFAOYSA-N Ammonia Chemical compound N QGZKDVFQNNGYKY-UHFFFAOYSA-N 0.000 description 24
- 238000001914 filtration Methods 0.000 description 24
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 23
- 239000003798 L01XE11 - Pazopanib Substances 0.000 description 22
- 229960000639 pazopanib Drugs 0.000 description 22
- 239000003480 eluent Substances 0.000 description 19
- 238000005160 1H NMR spectroscopy Methods 0.000 description 18
- UXKLQDCALAWFIU-VKNDCNMPSA-N (6r,7r)-1-[(4s,5r)-4-acetyloxy-5-methyl-3-methylidene-6-phenylhexyl]-4,7-dihydroxy-6-tetradecoxy-2,8-dioxabicyclo[3.2.1]octane-3,4,5-tricarboxylic acid Chemical compound C([C@@H](C)[C@H](OC(C)=O)C(=C)CCC12[C@H](O)[C@H](C(O2)(C(O)=O)C(O)(C(O1)C(O)=O)C(O)=O)OCCCCCCCCCCCCCC)C1=CC=CC=C1 UXKLQDCALAWFIU-VKNDCNMPSA-N 0.000 description 17
- 230000000694 effects Effects 0.000 description 17
- 238000003756 stirring Methods 0.000 description 17
- 239000000706 filtrate Substances 0.000 description 16
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 16
- 238000002474 experimental method Methods 0.000 description 15
- 235000021463 dry cake Nutrition 0.000 description 14
- 238000001704 evaporation Methods 0.000 description 14
- 238000002330 electrospray ionisation mass spectrometry Methods 0.000 description 13
- 235000011167 hydrochloric acid Nutrition 0.000 description 13
- 230000002401 inhibitory effect Effects 0.000 description 13
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 12
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 12
- VXJPCEOTZNHHOA-UHFFFAOYSA-N [K].OC Chemical compound [K].OC VXJPCEOTZNHHOA-UHFFFAOYSA-N 0.000 description 12
- 229910021529 ammonia Inorganic materials 0.000 description 12
- 239000007788 liquid Substances 0.000 description 12
- 229910052700 potassium Inorganic materials 0.000 description 12
- 239000011591 potassium Substances 0.000 description 12
- 230000001376 precipitating effect Effects 0.000 description 12
- 238000005406 washing Methods 0.000 description 12
- 239000011780 sodium chloride Substances 0.000 description 11
- 230000000259 anti-tumor effect Effects 0.000 description 10
- 230000015572 biosynthetic process Effects 0.000 description 10
- 239000010410 layer Substances 0.000 description 10
- 125000000951 phenoxy group Chemical group [H]C1=C([H])C([H])=C(O*)C([H])=C1[H] 0.000 description 10
- 239000013641 positive control Substances 0.000 description 10
- 238000003786 synthesis reaction Methods 0.000 description 10
- CSNNHWWHGAXBCP-UHFFFAOYSA-L Magnesium sulfate Chemical compound [Mg+2].[O-][S+2]([O-])([O-])[O-] CSNNHWWHGAXBCP-UHFFFAOYSA-L 0.000 description 9
- 239000012895 dilution Substances 0.000 description 9
- 238000010790 dilution Methods 0.000 description 9
- 229940121372 histone deacetylase inhibitor Drugs 0.000 description 9
- 239000003276 histone deacetylase inhibitor Substances 0.000 description 9
- 230000003213 activating effect Effects 0.000 description 8
- 239000012065 filter cake Substances 0.000 description 8
- 239000005457 ice water Substances 0.000 description 8
- OIBZPYSOENKXEN-UHFFFAOYSA-N methyl 7-(4-nitrophenoxy)heptanoate Chemical compound COC(=O)CCCCCCOc1ccc(cc1)[N+]([O-])=O OIBZPYSOENKXEN-UHFFFAOYSA-N 0.000 description 8
- BJHCYTJNPVGSBZ-YXSASFKJSA-N 1-[4-[6-amino-5-[(Z)-methoxyiminomethyl]pyrimidin-4-yl]oxy-2-chlorophenyl]-3-ethylurea Chemical compound CCNC(=O)Nc1ccc(Oc2ncnc(N)c2\C=N/OC)cc1Cl BJHCYTJNPVGSBZ-YXSASFKJSA-N 0.000 description 6
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 description 6
- 108010053099 Vascular Endothelial Growth Factor Receptor-2 Proteins 0.000 description 6
- 238000013019 agitation Methods 0.000 description 6
- 239000007789 gas Substances 0.000 description 6
- MNWFXJYAOYHMED-UHFFFAOYSA-N heptanoic acid Chemical compound CCCCCCC(O)=O MNWFXJYAOYHMED-UHFFFAOYSA-N 0.000 description 6
- 238000010792 warming Methods 0.000 description 6
- ZYHQGITXIJDDKC-UHFFFAOYSA-N 2-[2-(2-aminophenyl)ethyl]aniline Chemical group NC1=CC=CC=C1CCC1=CC=CC=C1N ZYHQGITXIJDDKC-UHFFFAOYSA-N 0.000 description 5
- 206010059866 Drug resistance Diseases 0.000 description 5
- 239000000890 drug combination Substances 0.000 description 5
- 238000001035 drying Methods 0.000 description 5
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 5
- RXYIYUOOCZCTQP-UHFFFAOYSA-N 5-methylpyrimidine-2,4-diamine Chemical class CC1=CN=C(N)N=C1N RXYIYUOOCZCTQP-UHFFFAOYSA-N 0.000 description 4
- NIXOWILDQLNWCW-UHFFFAOYSA-M Acrylate Chemical compound [O-]C(=O)C=C NIXOWILDQLNWCW-UHFFFAOYSA-M 0.000 description 4
- DHMQDGOQFOQNFH-UHFFFAOYSA-M Aminoacetate Chemical compound NCC([O-])=O DHMQDGOQFOQNFH-UHFFFAOYSA-M 0.000 description 4
- NLXLAEXVIDQMFP-UHFFFAOYSA-N Ammonia chloride Chemical compound [NH4+].[Cl-] NLXLAEXVIDQMFP-UHFFFAOYSA-N 0.000 description 4
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 4
- ZHNUHDYFZUAESO-UHFFFAOYSA-N Formamide Chemical compound NC=O ZHNUHDYFZUAESO-UHFFFAOYSA-N 0.000 description 4
- 108010033040 Histones Proteins 0.000 description 4
- 108090000704 Tubulin Proteins 0.000 description 4
- 102000004243 Tubulin Human genes 0.000 description 4
- 210000000709 aorta Anatomy 0.000 description 4
- HUMNYLRZRPPJDN-UHFFFAOYSA-N benzaldehyde Chemical compound O=CC1=CC=CC=C1 HUMNYLRZRPPJDN-UHFFFAOYSA-N 0.000 description 4
- WPYMKLBDIGXBTP-UHFFFAOYSA-N benzoic acid Chemical compound OC(=O)C1=CC=CC=C1 WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 description 4
- 125000003236 benzoyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C(*)=O 0.000 description 4
- 210000004204 blood vessel Anatomy 0.000 description 4
- 230000004663 cell proliferation Effects 0.000 description 4
- 210000000038 chest Anatomy 0.000 description 4
- 239000000460 chlorine Substances 0.000 description 4
- 229910052801 chlorine Inorganic materials 0.000 description 4
- BTCSSZJGUNDROE-UHFFFAOYSA-N gamma-aminobutyric acid Chemical compound NCCCC(O)=O BTCSSZJGUNDROE-UHFFFAOYSA-N 0.000 description 4
- 238000012360 testing method Methods 0.000 description 4
- NEAQRZUHTPSBBM-UHFFFAOYSA-N 2-hydroxy-3,3-dimethyl-7-nitro-4h-isoquinolin-1-one Chemical compound C1=C([N+]([O-])=O)C=C2C(=O)N(O)C(C)(C)CC2=C1 NEAQRZUHTPSBBM-UHFFFAOYSA-N 0.000 description 3
- TZKBVRDEOITLRB-UHFFFAOYSA-N 4-methyl-n-[4-[(4-methylpiperazin-1-yl)methyl]-3-(trifluoromethyl)phenyl]-3-[2-(1h-pyrazolo[3,4-b]pyridin-5-yl)ethynyl]benzamide Chemical compound C1CN(C)CCN1CC(C(=C1)C(F)(F)F)=CC=C1NC(=O)C1=CC=C(C)C(C#CC=2C=C3C=NNC3=NC=2)=C1 TZKBVRDEOITLRB-UHFFFAOYSA-N 0.000 description 3
- 239000004471 Glycine Substances 0.000 description 3
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 3
- 230000021736 acetylation Effects 0.000 description 3
- 238000006640 acetylation reaction Methods 0.000 description 3
- 239000003795 chemical substances by application Substances 0.000 description 3
- 230000001684 chronic effect Effects 0.000 description 3
- 230000006837 decompression Effects 0.000 description 3
- 150000004985 diamines Chemical class 0.000 description 3
- 150000002431 hydrogen Chemical class 0.000 description 3
- 239000011777 magnesium Substances 0.000 description 3
- 229910052749 magnesium Inorganic materials 0.000 description 3
- 239000012071 phase Substances 0.000 description 3
- 238000001953 recrystallisation Methods 0.000 description 3
- 239000002893 slag Substances 0.000 description 3
- SHAHPWSYJFYMRX-GDLCADMTSA-N (2S)-2-(4-{[(1R,2S)-2-hydroxycyclopentyl]methyl}phenyl)propanoic acid Chemical compound C1=CC([C@@H](C(O)=O)C)=CC=C1C[C@@H]1[C@@H](O)CCC1 SHAHPWSYJFYMRX-GDLCADMTSA-N 0.000 description 2
- ZYMCBJWUWHHVRX-UHFFFAOYSA-N (4-nitrophenyl)-phenylmethanone Chemical compound C1=CC([N+](=O)[O-])=CC=C1C(=O)C1=CC=CC=C1 ZYMCBJWUWHHVRX-UHFFFAOYSA-N 0.000 description 2
- VUDZSIYXZUYWSC-DBRKOABJSA-N (4r)-1-[(2r,4r,5r)-3,3-difluoro-4-hydroxy-5-(hydroxymethyl)oxolan-2-yl]-4-hydroxy-1,3-diazinan-2-one Chemical compound FC1(F)[C@H](O)[C@@H](CO)O[C@H]1N1C(=O)N[C@H](O)CC1 VUDZSIYXZUYWSC-DBRKOABJSA-N 0.000 description 2
- 239000005711 Benzoic acid Substances 0.000 description 2
- 206010009944 Colon cancer Diseases 0.000 description 2
- 102000004190 Enzymes Human genes 0.000 description 2
- 108090000790 Enzymes Proteins 0.000 description 2
- 102100022537 Histone deacetylase 6 Human genes 0.000 description 2
- 102000006947 Histones Human genes 0.000 description 2
- 101000899330 Homo sapiens Histone deacetylase 6 Proteins 0.000 description 2
- HPKJGHVHQWJOOT-ZJOUEHCJSA-N N-[(2S)-3-cyclohexyl-1-oxo-1-({(2S)-1-oxo-3-[(3S)-2-oxopyrrolidin-3-yl]propan-2-yl}amino)propan-2-yl]-1H-indole-2-carboxamide Chemical compound C1C(CCCC1)C[C@H](NC(=O)C=1NC2=CC=CC=C2C=1)C(=O)N[C@@H](C[C@H]1C(=O)NCC1)C=O HPKJGHVHQWJOOT-ZJOUEHCJSA-N 0.000 description 2
- WWGBHDIHIVGYLZ-UHFFFAOYSA-N N-[4-[3-[[[7-(hydroxyamino)-7-oxoheptyl]amino]-oxomethyl]-5-isoxazolyl]phenyl]carbamic acid tert-butyl ester Chemical compound C1=CC(NC(=O)OC(C)(C)C)=CC=C1C1=CC(C(=O)NCCCCCCC(=O)NO)=NO1 WWGBHDIHIVGYLZ-UHFFFAOYSA-N 0.000 description 2
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical compound [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 description 2
- 239000005864 Sulphur Substances 0.000 description 2
- IBEDDHUHZBDXGB-OEJISELMSA-N Tubulysin A Chemical compound N([C@@H]([C@@H](C)CC)C(=O)N(COC(=O)CC(C)C)[C@H](C[C@@H](OC(C)=O)C=1SC=C(N=1)C(=O)N[C@H](C[C@H](C)C(O)=O)CC=1C=CC(O)=CC=1)C(C)C)C(=O)[C@H]1CCCCN1C IBEDDHUHZBDXGB-OEJISELMSA-N 0.000 description 2
- 102000005789 Vascular Endothelial Growth Factors Human genes 0.000 description 2
- 108010019530 Vascular Endothelial Growth Factors Proteins 0.000 description 2
- YVNRUPSDZZZUQJ-UHFFFAOYSA-N [O].NC1=CC=CC=C1 Chemical compound [O].NC1=CC=CC=C1 YVNRUPSDZZZUQJ-UHFFFAOYSA-N 0.000 description 2
- 230000004913 activation Effects 0.000 description 2
- 235000019270 ammonium chloride Nutrition 0.000 description 2
- 239000002246 antineoplastic agent Substances 0.000 description 2
- 229940041181 antineoplastic drug Drugs 0.000 description 2
- YAVVGPBYBUYPSR-UHFFFAOYSA-N benzene;oxygen Chemical compound [O].C1=CC=CC=C1 YAVVGPBYBUYPSR-UHFFFAOYSA-N 0.000 description 2
- 235000010233 benzoic acid Nutrition 0.000 description 2
- 239000012043 crude product Substances 0.000 description 2
- 239000013078 crystal Substances 0.000 description 2
- UKJLNMAFNRKWGR-UHFFFAOYSA-N cyclohexatrienamine Chemical group NC1=CC=C=C[CH]1 UKJLNMAFNRKWGR-UHFFFAOYSA-N 0.000 description 2
- 230000008406 drug-drug interaction Effects 0.000 description 2
- 210000002889 endothelial cell Anatomy 0.000 description 2
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 2
- 229960003692 gamma aminobutyric acid Drugs 0.000 description 2
- 238000001727 in vivo Methods 0.000 description 2
- 230000005764 inhibitory process Effects 0.000 description 2
- JMMWKPVZQRWMSS-UHFFFAOYSA-N isopropanol acetate Natural products CC(C)OC(C)=O JMMWKPVZQRWMSS-UHFFFAOYSA-N 0.000 description 2
- 239000006210 lotion Substances 0.000 description 2
- 230000001394 metastastic effect Effects 0.000 description 2
- 206010061289 metastatic neoplasm Diseases 0.000 description 2
- 238000011580 nude mouse model Methods 0.000 description 2
- 239000012044 organic layer Substances 0.000 description 2
- 239000012074 organic phase Substances 0.000 description 2
- QNGNSVIICDLXHT-UHFFFAOYSA-N para-ethylbenzaldehyde Natural products CCC1=CC=C(C=O)C=C1 QNGNSVIICDLXHT-UHFFFAOYSA-N 0.000 description 2
- 239000003208 petroleum Substances 0.000 description 2
- 230000002062 proliferating effect Effects 0.000 description 2
- 238000011160 research Methods 0.000 description 2
- 238000001228 spectrum Methods 0.000 description 2
- 238000013517 stratification Methods 0.000 description 2
- 239000000758 substrate Substances 0.000 description 2
- 230000001629 suppression Effects 0.000 description 2
- 230000004083 survival effect Effects 0.000 description 2
- 210000003606 umbilical vein Anatomy 0.000 description 2
- JQSHBVHOMNKWFT-DTORHVGOSA-N varenicline Chemical compound C12=CC3=NC=CN=C3C=C2[C@H]2C[C@@H]1CNC2 JQSHBVHOMNKWFT-DTORHVGOSA-N 0.000 description 2
- 238000001262 western blot Methods 0.000 description 2
- KORCWPOBTZTAFI-YVTYUBGGSA-N (2s,3r,4r,5s,6r)-2-[7-chloro-6-[(4-cyclopropylphenyl)methyl]-2,3-dihydro-1-benzofuran-4-yl]-6-(hydroxymethyl)oxane-3,4,5-triol Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1C1=CC(CC=2C=CC(=CC=2)C2CC2)=C(Cl)C2=C1CCO2 KORCWPOBTZTAFI-YVTYUBGGSA-N 0.000 description 1
- YZWKKMVJZFACSU-UHFFFAOYSA-N 1-bromopentane Chemical compound CCCCCBr YZWKKMVJZFACSU-UHFFFAOYSA-N 0.000 description 1
- RTBFRGCFXZNCOE-UHFFFAOYSA-N 1-methylsulfonylpiperidin-4-one Chemical compound CS(=O)(=O)N1CCC(=O)CC1 RTBFRGCFXZNCOE-UHFFFAOYSA-N 0.000 description 1
- XJPZKYIHCLDXST-UHFFFAOYSA-N 4,6-dichloropyrimidine Chemical compound ClC1=CC(Cl)=NC=N1 XJPZKYIHCLDXST-UHFFFAOYSA-N 0.000 description 1
- QCQCHGYLTSGIGX-GHXANHINSA-N 4-[[(3ar,5ar,5br,7ar,9s,11ar,11br,13as)-5a,5b,8,8,11a-pentamethyl-3a-[(5-methylpyridine-3-carbonyl)amino]-2-oxo-1-propan-2-yl-4,5,6,7,7a,9,10,11,11b,12,13,13a-dodecahydro-3h-cyclopenta[a]chrysen-9-yl]oxy]-2,2-dimethyl-4-oxobutanoic acid Chemical compound N([C@@]12CC[C@@]3(C)[C@]4(C)CC[C@H]5C(C)(C)[C@@H](OC(=O)CC(C)(C)C(O)=O)CC[C@]5(C)[C@H]4CC[C@@H]3C1=C(C(C2)=O)C(C)C)C(=O)C1=CN=CC(C)=C1 QCQCHGYLTSGIGX-GHXANHINSA-N 0.000 description 1
- 102000007469 Actins Human genes 0.000 description 1
- 108010085238 Actins Proteins 0.000 description 1
- 208000001333 Colorectal Neoplasms Diseases 0.000 description 1
- 201000008808 Fibrosarcoma Diseases 0.000 description 1
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 1
- 102100039996 Histone deacetylase 1 Human genes 0.000 description 1
- 102100039999 Histone deacetylase 2 Human genes 0.000 description 1
- 101001035024 Homo sapiens Histone deacetylase 1 Proteins 0.000 description 1
- 101001035011 Homo sapiens Histone deacetylase 2 Proteins 0.000 description 1
- 102100020870 La-related protein 6 Human genes 0.000 description 1
- 108050008265 La-related protein 6 Proteins 0.000 description 1
- 208000028018 Lymphocytic leukaemia Diseases 0.000 description 1
- 108010058398 Macrophage Colony-Stimulating Factor Receptor Proteins 0.000 description 1
- 208000035490 Megakaryoblastic Acute Leukemia Diseases 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 241000699660 Mus musculus Species 0.000 description 1
- 208000033776 Myeloid Acute Leukemia Diseases 0.000 description 1
- 240000002853 Nelumbo nucifera Species 0.000 description 1
- 235000006508 Nelumbo nucifera Nutrition 0.000 description 1
- 235000006510 Nelumbo pentapetala Nutrition 0.000 description 1
- 108010051742 Platelet-Derived Growth Factor beta Receptor Proteins 0.000 description 1
- 102000018967 Platelet-Derived Growth Factor beta Receptor Human genes 0.000 description 1
- 108010014608 Proto-Oncogene Proteins c-kit Proteins 0.000 description 1
- 102000016971 Proto-Oncogene Proteins c-kit Human genes 0.000 description 1
- 208000006265 Renal cell carcinoma Diseases 0.000 description 1
- 201000000582 Retinoblastoma Diseases 0.000 description 1
- 108010078814 Tumor Suppressor Protein p53 Proteins 0.000 description 1
- 102000015098 Tumor Suppressor Protein p53 Human genes 0.000 description 1
- 229940124674 VEGF-R inhibitor Drugs 0.000 description 1
- 108010073929 Vascular Endothelial Growth Factor A Proteins 0.000 description 1
- 108010053096 Vascular Endothelial Growth Factor Receptor-1 Proteins 0.000 description 1
- 108010053100 Vascular Endothelial Growth Factor Receptor-3 Proteins 0.000 description 1
- 102100033178 Vascular endothelial growth factor receptor 1 Human genes 0.000 description 1
- 102100033179 Vascular endothelial growth factor receptor 3 Human genes 0.000 description 1
- 125000002777 acetyl group Chemical group [H]C([H])([H])C(*)=O 0.000 description 1
- 208000013593 acute megakaryoblastic leukemia Diseases 0.000 description 1
- 208000020700 acute megakaryocytic leukemia Diseases 0.000 description 1
- 150000001299 aldehydes Chemical class 0.000 description 1
- JFCQEDHGNNZCLN-UHFFFAOYSA-N anhydrous glutaric acid Natural products OC(=O)CCCC(O)=O JFCQEDHGNNZCLN-UHFFFAOYSA-N 0.000 description 1
- 230000001772 anti-angiogenic effect Effects 0.000 description 1
- 230000001093 anti-cancer Effects 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 230000033228 biological regulation Effects 0.000 description 1
- 230000000903 blocking effect Effects 0.000 description 1
- 230000001413 cellular effect Effects 0.000 description 1
- 208000019065 cervical carcinoma Diseases 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 238000002512 chemotherapy Methods 0.000 description 1
- 208000009060 clear cell adenocarcinoma Diseases 0.000 description 1
- 208000029742 colonic neoplasm Diseases 0.000 description 1
- 201000010989 colorectal carcinoma Diseases 0.000 description 1
- 229940126214 compound 3 Drugs 0.000 description 1
- 235000009508 confectionery Nutrition 0.000 description 1
- 238000002425 crystallisation Methods 0.000 description 1
- 230000008025 crystallization Effects 0.000 description 1
- 229960002465 dabrafenib Drugs 0.000 description 1
- BFSMGDJOXZAERB-UHFFFAOYSA-N dabrafenib Chemical compound S1C(C(C)(C)C)=NC(C=2C(=C(NS(=O)(=O)C=3C(=CC=CC=3F)F)C=CC=2)F)=C1C1=CC=NC(N)=N1 BFSMGDJOXZAERB-UHFFFAOYSA-N 0.000 description 1
- 230000007547 defect Effects 0.000 description 1
- 230000007812 deficiency Effects 0.000 description 1
- 230000000994 depressogenic effect Effects 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 238000009510 drug design Methods 0.000 description 1
- 238000007876 drug discovery Methods 0.000 description 1
- 239000003596 drug target Substances 0.000 description 1
- 201000006585 gastric adenocarcinoma Diseases 0.000 description 1
- 238000010438 heat treatment Methods 0.000 description 1
- RGZRSLKIOCHTSI-UHFFFAOYSA-N hydron;n-methylhydroxylamine;chloride Chemical compound Cl.CNO RGZRSLKIOCHTSI-UHFFFAOYSA-N 0.000 description 1
- 238000003119 immunoblot Methods 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 210000003734 kidney Anatomy 0.000 description 1
- 230000002147 killing effect Effects 0.000 description 1
- 208000003747 lymphoid leukemia Diseases 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- UOBSVARXACCLLH-UHFFFAOYSA-N monomethyl adipate Chemical compound COC(=O)CCCCC(O)=O UOBSVARXACCLLH-UHFFFAOYSA-N 0.000 description 1
- 230000035772 mutation Effects 0.000 description 1
- 208000025113 myeloid leukemia Diseases 0.000 description 1
- 150000004987 o-phenylenediamines Chemical class 0.000 description 1
- 150000002894 organic compounds Chemical class 0.000 description 1
- RZXMPPFPUUCRFN-UHFFFAOYSA-N p-toluidine Chemical compound CC1=CC=C(N)C=C1 RZXMPPFPUUCRFN-UHFFFAOYSA-N 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 239000000651 prodrug Substances 0.000 description 1
- 229940002612 prodrug Drugs 0.000 description 1
- 230000002035 prolonged effect Effects 0.000 description 1
- 125000006239 protecting group Chemical group 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 239000000376 reactant Substances 0.000 description 1
- 229940124617 receptor tyrosine kinase inhibitor Drugs 0.000 description 1
- 108091008598 receptor tyrosine kinases Proteins 0.000 description 1
- 102000027426 receptor tyrosine kinases Human genes 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 208000015347 renal cell adenocarcinoma Diseases 0.000 description 1
- 238000012827 research and development Methods 0.000 description 1
- 230000002441 reversible effect Effects 0.000 description 1
- 238000012552 review Methods 0.000 description 1
- 238000007086 side reaction Methods 0.000 description 1
- 238000010898 silica gel chromatography Methods 0.000 description 1
- 150000003384 small molecules Chemical class 0.000 description 1
- 239000012453 solvate Substances 0.000 description 1
- 238000007920 subcutaneous administration Methods 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 230000002195 synergetic effect Effects 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 230000002103 transcriptional effect Effects 0.000 description 1
- 210000004881 tumor cell Anatomy 0.000 description 1
- 230000004614 tumor growth Effects 0.000 description 1
- 230000002792 vascular Effects 0.000 description 1
- 230000035899 viability Effects 0.000 description 1
- BFDBKMOZYNOTPK-UHFFFAOYSA-N vonoprazan Chemical compound C=1C=CN=CC=1S(=O)(=O)N1C=C(CNC)C=C1C1=CC=CC=C1F BFDBKMOZYNOTPK-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
- C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
- C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
- C07D239/46—Two or more oxygen, sulphur or nitrogen atoms
- C07D239/48—Two nitrogen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Epidemiology (AREA)
- Hematology (AREA)
- Oncology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
Abstract
The present invention relates to HDAC and bis- target spot inhibitor of VEGFR and its preparation method and application based on pazopanib structure.The compound has structure shown in general formula I, II or III.The present invention also provides the preparation method of such compound and in preparation prevention or treatment and the application in tumor-related illness drug.
Description
Technical field
The invention belongs to organic compound synthesis and medical applications technical field, and in particular to based on pazopanib structure
Bis- target spot inhibitor of HDAC and VEGFR and its preparation method and application.
Background technique
Pazopanib Pazopanib is a Mutiple Targets receptor tyrosine kinase inhibitor, to vascular endothelial growth factor
Three hypotypes (VEGFR-1, VEGFR-2, VEGFR-3) of receptor VEGFR and associated receptor tyrosine kinase (PDGFR
β, c-Kit, FGF-R1, c-fms) show preferable inhibitory activity (IC50:10,30,47,84,74,140,146 nM)
(Harris,pHilip A.etc.,Journal of Medicinal Chemistry 2008,51,4632).Pazopanib in
In October, 2009 ratifies listing for there is the advanced stage kidney of the past chemotherapy experience patient thin by U.S. Food and Drug Administration FDA
The treatment (Bukowski.etc., Nature Reviews Drug Discovery, 2010,9,17) of born of the same parents' cancer, at 2012 years 04
The moon is used for treatment (Wilky, the Breelyn A.etc., Current of advanced stage soft tissue sarcoma by FDA approval listing again
opinion in oncology,2013,25,373).However in recent years, pazopanib occurs low in process of clinical application
It is the problem of response rate and drug resistance (Gotink K J.etc., Cellular Oncology, 2015,38,119), medication combined
Using and research and development multiple target point drug be enhance tumour to drug susceptibility and reduce drug resistance of tumor a strategy.
Histon deacetylase (HDAC) HDACs is one group of enzyme of internal regulation acetylation of histone level, the acetyl of histone
Change level has important influence to the transcriptional regulatory of chromatinic structure and gene, HDACs mutation and unconventionality expression usually with
The generation of tumour is closely related.HDACs inhibitor has been shown to have antitumor action, at present existing 5 small molecule HDAC suppression
Preparation go through listing for a variety of blood tumors treatment (Li X.etc., Current Drug Targets, 2014,15,
622).With gradually illustrating for HDAC and VEGF/VEGFR signal path relationship, pazopanib and hdac inhibitor use in conjunction
Cause the interest of researcher.The study found that the combination of pazopanib and hdac inhibitor (VPA, SAHA) are in soft tissue sarcoma
In show the inside and outside antitumor action of addition or collaboration, and drug combination can reverse pazopanib drug-resistant tumor strain
Drug resistance (Tavallai S.etc., Cancer Biology&Therapy, 2014,15,578).Hdac inhibitor AR-42 with
The work of the killing to the drug resistant melanoma of dabrafenib/Trimetinib is shown in the combination of pazopanib experiment in vivo and in vitro
With, synergistic effect with activate a plurality of signal path related (Booth L.etc., Oncotarget, 2017,8,16367).
Researches show that be mutated when pazopanib and hdac inhibitor SAHA drug combination to TP53 for one clinical I phase of report in 2015
Especially the tumour patient of metastatic sarcoma and metastatic colorectal carcinoma shows apparent curative effect, wherein position Progression free survival
Phase and middle position Overall survival are obviously prolonged (Fu S.etc., Annals of Oncology, 2015,26,1012).2017 most
Researches show that hdac inhibitor abexinost and pazopanib combination to have good tolerance for the clinical I phase newly reported
Property, and can effectively overcome pazopanib drug resistance (Aggarwal, Rahul, etc., Journal of Clinical Oncology,
2017,35,1231)。
Clinically, the anti-tumor drug use in conjunction of different role mechanism has been considered as avoiding the standard side of drug resistance
Case, but drug combination there is a problem of it is following: (1) drug combination pharmacokinetics is complicated, and drug-drug interactions are bad
Reaction it is difficult to predict;(2) compatibility of different pharmaceutical and dosage setting clinically have difficulties.Multiple target point drug refers to while making
For the single medicine molecule of multiple target spots, multiple target point drug not only has the advantages of drug combination, but also overcomes joint and use
Some defects of medicine.Multiple target point drug pharmacokinetics are simple, avoid drug-drug interaction, safer, improve
The compliance of patient becomes a popular direction of current antineoplastic drug design.Currently, based on pazopanib structure
The bis- target spot inhibitor of HDAC and VEGFR have no relevant report in the prior art.
Summary of the invention
In view of the deficiencies of the prior art, the present invention provides based on pazopanib structure HDAC and VEGFR bis- target spots suppression
Preparation, the present invention also provides the preparation method of above compound and purposes.
The technical solution of the present invention is as follows:
One, the bis- target spot inhibitor of HDAC and VEGFR based on pazopanib structure
The present invention contains the bis- target spot inhibitor of the HDAC/VEGFR based on pazopanib structure, pharmaceutically acceptable
Salt, solvate or prodrug have structure shown in following general formula I, II or III:
Wherein:
X is
N is 0~9;
Y is
It is preferred according to the present invention,
X is in contraposition or meta position in Y and II in general formula I;
X is
N is 0~7;
Y is
It is further preferred that above compound is one of following:
4- ((4- ((2,3- dimethyl -2H- indazole -6- base) (methyl) amino) pyrimidine -2-base) amino)-N- hydroxy benzenes first
Amide (6a),
3- ((4- ((2,3- dimethyl -2H- indazole -6- base) (methyl) amino) pyrimidine -2-base) amino)-N- hydroxy benzenes first
Amide (6b),
5- ((4- ((2,3- dimethyl -2H- indazole -6- base) (methyl) amino) pyrimidine -2-base) amino)-N- hydroxyl -2-
Methyl benzamide (6c),
N- (2- aminophenyl) -4- ((4- ((2,3- dimethyl -2H- indazole -6- base) (methyl) amino) pyrimidine -2-base)
Amino) benzamide (6d),
N- (2- aminophenyl) -3- ((4- ((2,3- dimethyl -2H- indazole -6- base) (methyl) amino) pyrimidine -2-base)
Amino) benzamide (6e),
(E) -3- (4- ((4- ((2,3- dimethyl -2H- indazole -6- base) (methyl) amino) pyrimidine -2-base) amino) benzene
Base)-N- hydroxyacrylamide (10a),
(E) -3- (3- ((4- ((2,3- dimethyl -2H- indazole -6- base) (methyl) amino) pyrimidine -2-base) amino) benzene
Base)-N- hydroxyacrylamide (10b),
4- ((4- ((2,3- dimethyl -2H- indazole -6- base) (methyl) amino) pyrimidine -2-base) amino)-N- (2- (hydroxyl
Amine) -2- oxoethyl) benzamide (13a),
4- ((4- ((2,3- dimethyl -2H- indazole -6- base) (methyl) amino) pyrimidine -2-base) amino)-N- (3- (hydroxyl
Amine) -3- oxopropyl) benzamide (13b),
4- ((4- ((2,3- dimethyl -2H- indazole -6- base) (methyl) amino) pyrimidine -2-base) amino)-N- (4- (hydroxyl
Amine) -4- oxo butyl) benzamide (13c),
4- ((4- ((2,3- dimethyl -2H- indazole -6- base) (methyl) amino) pyrimidine -2-base) amino)-N- (5- (hydroxyl
Amine) -5- oxopentyl) benzamide (13d),
4- ((4- ((2,3- dimethyl -2H- indazole -6- base) (methyl) amino) pyrimidine -2-base) amino)-N- (6- (hydroxyl
Amine) -6- oxo-hexyl) benzamide (13e),
4- ((4- ((2,3- dimethyl -2H- indazole -6- base) (methyl) amino) pyrimidine -2-base) amino)-N- (7- (hydroxyl
Amine) -7- oxo heptyl) benzamide (13f),
4- ((4- ((2,3- dimethyl -2H- indazole -6- base) (methyl) amino) pyrimidine -2-base) amino)-N- (8- (hydroxyl
Amine) -8- oxo octyl) benzamide (13g),
3- ((4- ((2,3- dimethyl -2H- indazole -6- base) (methyl) amino) pyrimidine -2-base) amino)-N- (6- (hydroxyl
Amine) -6- oxo-hexyl) benzamide (13h),
5- ((4- ((2,3- dimethyl -2H- indazole -6- base) (methyl) amino) pyrimidine -2-base) amino)-N- (6- (hydroxyl
Amine) -6- oxo-hexyl) -2- methyl benzamide (13i),
N- (2- ((2- aminophenyl) amino) -2- oxoethyl) -4- ((4- ((2,3- dimethyl -2H- indazole -6- base)
(methyl) amino) pyrimidine -2-base) amino) benzamide (14a),
N- (3- ((2- aminophenyl) amino) -3- oxopropyl) -4- ((4- ((2,3- dimethyl -2H- indazole -6- base)
(methyl) amino) pyrimidine -2-base) amino) benzamide (14b),
N- (4- ((2- aminophenyl) amino) -4- oxo butyl) -4- ((4- ((2,3- dimethyl -2H- indazole -6- base)
(methyl) amino) pyrimidine -2-base) amino) benzamide (14c),
N- (5- ((2- aminophenyl) amino) -5- oxopentyl) -4- ((4- ((2,3- dimethyl -2H- indazole -6- base)
(methyl) amino) pyrimidine -2-base) amino) benzamide (14d),
N- (6- ((2- aminophenyl) amino) -6- oxo-hexyl) -4- ((4- ((2,3- dimethyl -2H- indazole -6- base)
(methyl) amino) pyrimidine -2-base) amino) benzamide (14e),
N- (7- ((2- aminophenyl) amino) -7- oxo heptyl) -4- ((4- ((2,3- dimethyl -2H- indazole -6- base)
(methyl) amino) pyrimidine -2-base) amino) benzamide (14f),
N- (8- ((2- aminophenyl) amino) -8- oxo octyl) -4- ((4- ((2,3- dimethyl -2H- indazole -6- base)
(methyl) amino) pyrimidine -2-base) amino) benzamide (14g),
2- (4- ((4- ((2,3- dimethyl -2H- indazole -6- base) (methyl) amino) pyrimidine -2-base) amino) phenoxy group) -
N- hydroxyl acetamide (19a),
3- (4- ((4- ((2,3- dimethyl -2H- indazole -6- base) (methyl) amino) pyrimidine -2-base) amino) phenoxy group) -
N- hydroxypropanamide (19b),
4- (4- ((4- ((2,3- dimethyl -2H- indazole -6- base) (methyl) amino) pyrimidine -2-base) amino) phenoxy group) -
N- hydroxybutyrate amide (19c),
5- (4- ((4- ((2,3- dimethyl -2H- indazole -6- base) (methyl) amino) pyrimidine -2-base) amino) phenoxy group) -
N- hydroxyvaleramide (19d),
6- (4- ((4- ((2,3- dimethyl -2H- indazole -6- base) (methyl) amino) pyrimidine -2-base) amino) phenoxy group) -
N- hydroxyl hexanamide (19e),
7- (4- ((4- ((2,3- dimethyl -2H- indazole -6- base) (methyl) amino) pyrimidine -2-base) amino) phenoxy group) -
N- hydroxyl heptamide (19f),
8- (4- ((4- ((2,3- dimethyl -2H- indazole -6- base) (methyl) amino) pyrimidine -2-base) amino) phenoxy group) -
N- hydroxy capryloyl amine (19g),
N1(4- ((4- ((2,3- dimethyl -2H- indazole -6- base) (methyl) amino) pyrimidine -2-base) amino) phenyl) -
N3Hydroxyl malonamide (23a),
N1(4- ((4- ((2,3- dimethyl -2H- indazole -6- base) (methyl) amino) pyrimidine -2-base) amino) phenyl) -
N4Hydroxy-succinamide (23b),
N1(4- ((4- ((2,3- dimethyl -2H- indazole -6- base) (methyl) amino) pyrimidine -2-base) amino) phenyl) -
N5Hydroxyl glutaramide (23c),
N1(4- ((4- ((2,3- dimethyl -2H- indazole -6- base) (methyl) amino) pyrimidine -2-base) amino) phenyl) -
N6Hydroxyl adipamide (23d),
N1(4- ((4- ((2,3- dimethyl -2H- indazole -6- base) (methyl) amino) pyrimidine -2-base) amino) phenyl) -
N7Hydroxyl heptanedioyl amine (23e),
N1(4- ((4- ((2,3- dimethyl -2H- indazole -6- base) (methyl) amino) pyrimidine -2-base) amino) phenyl) -
N8Hydroxyl suberamide (23f),
N1(4- ((4- ((2,3- dimethyl -2H- indazole -6- base) (methyl) amino) pyrimidine -2-base) amino) phenyl) -
N9Hydroxyl nonanedioyl amine (23g),
2- ((4- ((4- ((2,3- dimethyl -2H- indazole -6- base) (methyl) amino) pyrimidine -2-base) amino) phenyl) ammonia
Base)-N- hydroxyl acetamide (28a)
3- ((4- ((4- ((2,3- dimethyl -2H- indazole -6- base) (methyl) amino) pyrimidine -2-base) amino) phenyl) ammonia
Base)-N- hydroxypropanamide (28b)
4- ((4- ((4- ((2,3- dimethyl -2H- indazole -6- base) (methyl) amino) pyrimidine -2-base) amino) phenyl) ammonia
Base)-N- hydroxybutyrate amide (28c)
5- ((4- ((4- ((2,3- dimethyl -2H- indazole -6- base) (methyl) amino) pyrimidine -2-base) amino) phenyl) ammonia
Base)-N- hydroxyvaleramide (28d)
6- ((4- ((4- ((2,3- dimethyl -2H- indazole -6- base) (methyl) amino) pyrimidine -2-base) amino) phenyl) ammonia
Base)-N- hydroxyl amide (28e)
7- ((4- ((4- ((2,3- dimethyl -2H- indazole -6- base) (methyl) amino) pyrimidine -2-base) amino) phenyl) ammonia
Base)-N- hydroxyl heptamide (28f) or
8- ((4- ((4- ((2,3- dimethyl -2H- indazole -6- base) (methyl) amino) pyrimidine -2-base) amino) phenyl) ammonia
Base)-N- hydroxy capryloyl amine (28g).
Two, the preparation method of the bis- target spot inhibitor of HDAC and VEGFR based on pazopanib structure
The present invention contains the preparation method of HDAC and the bis- target spot inhibitor of VEGFR based on pazopanib structure, is following
One of method:
(1) with 2,3- dimethyl -6- amino -2H- indazole for starting material, with 2,4- under sodium bicarbonate alkaline condition
Dichloro pyrimidine occurs nucleophilic substitution and obtains intermediate 2, during intermediate 2 obtains under cesium carbonate catalysis, with iodomethane reaction
Mesosome 3, intermediate 3 occur nucleophilic substitution from different substituted aniline under concentrated hydrochloric acid catalysis and obtain key intermediate 4, in
Mesosome 4 is protected to obtain intermediate 5 through methyl esters, and intermediate 5 obtains final product 6a-6c through the ammonolysis reaction of ester;Furthermore intermediate 4a-
4b and o-phenylenediamine obtain final product 6d-6e through amide condensed.
Reaction equation is as follows:
The phenyl ring of wherein 4a, 5a, 6a, 6d are that contraposition replaces, 4b, 5b, and the phenyl ring of 6b, 6e are that meta position replaces.
Reagent and condition in above-mentioned reaction equation: (a) 2,4- dichloro pyrimidine, sodium bicarbonate, dehydrated alcohol, reflux, 4h;
(b) cesium carbonate, iodomethane, n,N-Dimethylformamide, room temperature, 2h;(c) isopropanol, concentrated hydrochloric acid, reflux, 4h;(d) O- benzo
Triazole-N, N, N', N'- tetramethylurea tetrafluoro boric acid, triethylamine, o-phenylenediamine, n,N-Dimethylformamide, 0 DEG C-room temperature,
Overnight;(e) anhydrous methanol, thionyl chloride flow back, overnight;(f) hydroxylamine hydrochloride, potassium hydroxide, anhydrous methanol, room temperature, 2h.
The different aniline replaced are as follows: p-aminobenzoic acid, gavaculine or 5- amino-2-methyl benzene first
Acid.
Preferred according to the present invention, specific preparation process is as follows:
4- ((4- ((2,3- dimethyl -2H- indazole -6- base) (methyl) amino) pyrimidine -2-base) amino)-N- hydroxy benzenes first
The preparation method of amide (6a), steps are as follows:
(1) preparation of N- (2- chlorine pyrimidine-4-yl) -2,3- dimethyl -6- amino -2H- indazole (2)
By 2,3- dimethyl -6- amino -2H- indazole 5.00g, 2,4- dichloro pyrimidine 13.9g, and sodium bicarbonate 10.4g,
It is dissolved in 100mL dehydrated alcohol, is heated to 79 DEG C, flow back after 4h, cool down to room temperature, filter, filter cake ethyl acetate is abundant
Filtrate is collected in washing, is concentrated under reduced pressure, and removes solvent, pale solid is obtained by filtration after being sufficiently beaten with ethyl acetate, uses methanol
7.64g product 2 is obtained after recrystallization, is white solid.
(2) N- (2- chlorine pyrimidine-4-yl)-N, the preparation of 2,3- trimethyl -2H- indazole -6- amine (3)
Previous step product 2 1.00g and cesium carbonate 2.40g are added in 50mL n,N-Dimethylformamide, room temperature is anti-
20min is answered, iodomethane 0.78g is then slowly added into, finishes, 2h is reacted at room temperature, reaction solution is poured into ice water, is precipitated immediately big
Faint yellow solid is measured, filtering after drying, obtains 1.06g product 3 with re-crystallizing in ethyl acetate, is light yellow crystal.
(3) 4- ((4- ((2,3- dimethyl -2H- indazole -6- base) (methyl) amino) pyrimidine -2-base) amino) benzoic acid
The preparation of (4a)
It disperses intermediate 3 0.50g and p-aminobenzoic acid 0.36g in 30mL isopropanol, 2 drop concentrated hydrochloric acids is added, add
To 85 DEG C, back flow reaction 4h is cooled to room temperature heat, and filtering washs filter cake with isopropanol and ethyl acetate, is dried to obtain 0.53g
Product 4a is white solid.
(4) methyl 4- ((4- ((2,3- dimethyl -2H- indazole -6- base) (methyl) amino) pyrimidine -2-base) amino) benzene first
The preparation of acid esters (5a)
4a 0.50g is added in 50mL anhydrous methanol, thionyl chloride 0.60g is then added dropwise at 0 DEG C, finishes,
It after keeping the temperature 30min, is heated to flowing back after removing ice bath, after reacting 5h, solvent under reduced pressure be steamed, crude product recrystallisation from isopropanol
0.50g product 5a is obtained, is white solid.
(5) 4- ((4- ((2,3- dimethyl -2H- indazole -6- base) (methyl) amino) pyrimidine -2-base) amino)-N- hydroxyl
The preparation of benzamide (6a)
KOH 28.0g and hydroxylamine hydrochloride 23.53g are dissolved in respectively in 70mL and 120mL anhydrous methanol, obtain solution A and molten
Liquid B.Under ice bath, solution A is added dropwise in solution B, after stirring 2h, filters out precipitating, obtained filtrate is azanol potassium
Methanol solution.Compound 5a 0.20g is dissolved in 30mL azanol potassium solution, and after 1h is stirred at room temperature, it is most of molten that removing is concentrated under reduced pressure
Agent, residual residue adjust pH to 5-6 with 1M HCl, and white solid, filtering is precipitated, and dry cake obtains 80.6mg product 6a, is
White solid.
N- (2- aminophenyl) -4- ((4- ((2,3- dimethyl -2H- indazole -6- base) (methyl) amino) pyrimidine -2-base)
Amino) benzamide (6d) preparation method, steps are as follows:
(1) N- (2- aminophenyl) -4- ((4- ((2,3- dimethyl -2H- indazole -6- base) (methyl) amino) pyrimidine -2-
Base) amino) benzamide (6d) preparation
Intermediate 4a 0.50g is added in the anhydrous n,N-Dimethylformamide of 50mL, under ice bath, O- benzo three is added
After activating 30min, adjacent benzene is then added in nitrogen azoles-N, N, N', N'- tetramethylurea tetrafluoro boric acid 0.49g and triethylamine 0.26g
Diamines 0.17g, overnight, ethyl acetate dilution is added in reaction after the reaction was completed at room temperature, and n,N-Dimethylformamide is removed in washing,
Ethyl acetate layer saturated sodium bicarbonate solution and saturation NaCl solution are washed, and anhydrous magnesium sulfate is dry, and solvent is removed under reduced pressure, residual
Slag is purified to obtain 0.40g product 6d with silica gel column chromatography, is pale solid.
It (two) is starting material with intermediate 4, with N, the generation of O- dimethyl hydroxylamine hydrochloride is amide condensed to obtain intermediate 7,
Intermediate 7 is reduced to aldehyde intermediate 8 through tetrahydrochysene lithium aluminium, and Huo Naer-Wo Ziwo occurs for intermediate 8 and phosphonoacetate
Si-Ai Mengsi reacts to obtain intermediate 9, and intermediate 9 obtains final product 10 through the ammonolysis of ester.
Reaction equation is as follows:
The phenyl ring of wherein 4a, 7a, 8a, 9a, 10a are that contraposition replaces, 4b, 7b, 8b, 9b, and the phenyl ring of 10b is meta position substitution.
Reagent and condition in above-mentioned reaction equation: (a) N, O- dimethyl hydroxylamine hydrochloride, O- benzotriazole-N, N, N',
N'- tetramethylurea tetrafluoro boric acid, triethylamine, n,N-Dimethylformamide, room temperature, overnight;(b) tetrahydrochysene lithium aluminium, tetrahydrofuran ,-
20℃,4h;(c) phosphonoacetate, sodium hydride, tetrahydrofuran, 0 DEG C-room temperature, overnight;(d) hydroxylamine hydrochloride, hydroxide
Potassium, anhydrous methanol, room temperature, 2h.
Preferred according to the present invention, specific preparation process is as follows:
(E) -3- (4- ((4- ((2,3- dimethyl -2H- indazole -6- base) (methyl) amino) pyrimidine -2-base) amino) benzene
Base)-N- hydroxyacrylamide (10a) preparation:
(1) 4- ((4- ((2,3- dimethyl -2H- indazole -6- base) (methyl) amino) pyrimidine -2-base) amino)-N- methoxy
The preparation of base-N-methyl-benzamide (7a)
It is added to intermediate 4a 1.00g in anhydrous n,N-Dimethylformamide, under ice bath, three nitrogen of O- benzo is added
Then N, O- bis- is added after activating 30min in azoles-N, N, N', N'- tetramethylurea tetrafluoro boric acid 0.98g and triethylamine 0.52g
Methyl hydroxylamine hydrochloride 0.30g and triethylamine 0.31g, overnight, ethyl acetate dilution, washing is added in reaction after the reaction was completed at room temperature
N,N-Dimethylformamide is removed, ethyl acetate layer saturated sodium bicarbonate solution and saturation NaCl solution are washed, anhydrous slufuric acid
Magnesium is dry, and solvent is removed under reduced pressure, residue methylene chloride: methanol=35:1 volume ratio eluant, eluent carries out column chromatographic purifying and obtains
0.78g product 7a is white solid.
(2) 4- ((4- ((2,3- dimethyl -2H- indazole -6- base) (methyl) amino) pyrimidine -2-base) amino) benzaldehyde
The preparation of (8a)
Compound 7a 1.00g is dissolved in 50mL anhydrous tetrahydro furan, and is cooled to -40 DEG C in low-temp reaction instrument.To
It is slowly added to tetrahydrochysene lithium aluminium 0.26g in batches, this thermotonus 2h is maintained slowly carefully to be quenched after reaction with ice water
Reaction is to there is no bubble generations.Reaction solution is diluted with water, and is extracted with ethyl acetate, and merges organic layer, and saturation NaCl solution is washed
It washs, anhydrous magnesium sulfate is dry, solvent is concentrated under reduced pressure, residue methylene chloride: methanol=40:1 volume ratio eluant, eluent carries out column
Chromatographic purifying obtains 0.61g product 8a, is white solid.
(3) ethyl (E) -3- (4- ((4- ((2,3- dimethyl -2H- indazole -6- base) (methyl) amino) pyrimidine -2-base) ammonia
Base) phenyl) acrylate (9a) preparation
Phosphonoacetate 0.32g is added into 50mL anhydrous tetrahydro furan, is cooled to -5-0 DEG C, is slowly added to
NaH 0.16g, finishes, and stirs 20min, and the tetrahydrofuran solution of 8a 0.52g is then added dropwise, and room temperature reaction is stayed overnight, end of reaction
Afterwards, 10% ammonium chloride solution of 50mL is added, stirs stratification after 30min, after organic phase is dry, filtering is concentrated to get thick
Product.Residue methylene chloride: methanol=40:1 volume ratio eluant, eluent carries out column chromatographic purifying and obtains 0.48g product 9a, is white
Color solid.
(4) (E) -3- (4- ((4- ((2,3- dimethyl -2H- indazole -6- base) (methyl) amino) pyrimidine -2-base) amino)
Phenyl)-N- hydroxyacrylamide (10a) preparation
KOH 28.0g and hydroxylamine hydrochloride 23.53g are dissolved in respectively in 70mL and 120mL anhydrous methanol, obtain solution A and molten
Liquid B.Under ice bath, solution A is added dropwise in solution B, after stirring 2h, filters out precipitating, obtained filtrate is azanol potassium
Methanol solution.Compound 9a 0.50g is dissolved in 30mL azanol potassium solution, after 2h is stirred at room temperature, is concentrated under reduced pressure and is removed major part
Solvent, residual residue adjust pH to 5-6 with 1M HCl, and white solid, filtering is precipitated, and dry cake obtains 0.29g product 10a,
For white solid.
It (three) is starting material with intermediate 4, intermediate 4 is reacted with the amino-alkane methyl esters of different chain length through amide condensed
Intermediate 11 is obtained, intermediate 11 obtains final product 13 through the ammonolysis reaction of ester;Intermediate 11 is under the conditions of Sodium Hydroxide Alkaline
It is hydrolyzed to intermediate 12, intermediate 12 reacts to obtain final product 14 with o-phenylenediamine through amide condensed.
Reaction equation is as follows:
The phenyl ring of wherein 4a, 11a-11g, 12a-12g, 13a-13g, 14a-14g are that contraposition replaces, 4b, 11h, the benzene of 13h
Ring is meta position substitution, and n is 1~7.
Reagent and condition in above-mentioned reaction equation: (a) the amino-alkane methyl esters of different chain length, O- benzotriazole-N, N,
N', N'- tetramethylurea tetrafluoro boric acid, triethylamine, n,N-Dimethylformamide, room temperature, overnight;(b) hydroxylamine hydrochloride, hydroxide
Potassium, anhydrous methanol, room temperature, 2h;(c) 3M NaOH, methanol, room temperature, 2h;(d) o-phenylenediamine, O- benzotriazole-N, N, N',
N'- tetramethylurea tetrafluoro boric acid, triethylamine, n,N-Dimethylformamide, room temperature, overnight.
The amino-alkane methyl esters of the different chain length is: glycine methyl ester, 3- aminopropanoate, 4-Aminobutanoicacid first
Ester, 5- aminopentanoic acid methyl ester, 6-aminocaprolc acid methyl esters, 7- aminoheptylic acid methyl esters or 8- aminocaprylic acid methyl esters.
Preferred according to the present invention, specific preparation process is as follows:
4- ((4- ((2,3- dimethyl -2H- indazole -6- base) (methyl) amino) pyrimidine -2-base) amino)-N- (2- (hydroxyl
Amine) -2- oxoethyl) benzamide (13a) preparation method, steps are as follows:
(1) methyl (4- ((2,3- dimethyl -2H- indazole -6- base) (methyl) amino) pyrimidine -2-base) amino) benzoyl
Base) glycinate (11a) preparation
It is added to intermediate 4a 1.00g in anhydrous n,N-Dimethylformamide, under ice bath, three nitrogen of O- benzo is added
Then glycine is added after activating 30min in azoles-N, N, N', N'- tetramethylurea tetrafluoro boric acid 0.98g and triethylamine 0.52g
Methyl ester hydrochloride 0.39g, overnight, ethyl acetate dilution is added in reaction after the reaction was completed at room temperature, and N, N- dimethyl are removed in washing
Formamide, ethyl acetate layer saturated sodium bicarbonate solution and saturation NaCl solution are washed, and anhydrous magnesium sulfate is dry, is removed under reduced pressure
Solvent, residue are methylene chloride with eluant, eluent: methanol=30:1 volume ratio carries out column chromatographic purifying and obtains 0.87g product 11a, is
White solid.
(2) 4- ((4- ((2,3- dimethyl -2H- indazole -6- base) (methyl) amino) pyrimidine -2-base) amino)-N- (2-
(azanol) -2- oxoethyl) benzamide (13a) preparation
KOH 28.0g and hydroxylamine hydrochloride 23.53g are dissolved in respectively in 70mL and 120mL anhydrous methanol, obtain solution A and molten
Liquid B.Under ice bath, solution A is added dropwise in solution B, after stirring 2h, filters out precipitating, obtained filtrate is azanol potassium
Methanol solution.Compound 11a 0.50g is dissolved in 30mL azanol potassium solution, after 2h is stirred at room temperature, is concentrated under reduced pressure and is removed major part
Solvent, residual residue adjust pH to 5-6 with 1M HCl, and white solid, filtering is precipitated, and dry cake obtains 0.31g product 13a,
For white solid.
N- (2- ((2- aminophenyl) amino) -2- oxoethyl) -4- ((4- ((2,3- dimethyl -2H- indazole -6- base)
(methyl) amino) pyrimidine -2-base) amino) and benzamide (14a) preparation, steps are as follows:
(1) 4- ((4- ((2,3- dimethyl -2H- indazole -6- base) (methyl) amino) pyrimidine -2-base) amino) benzoyl
Base) glycine (12a) preparation
11a 1.00g is added in 30mL methanol, 5mL 3M NaOH solution is then added, stirs 4h at room temperature, is reacted
After, decompression boils off most of methanol, and residue adjusts pH to 5-6 with 1M HCl solution.Filtering, filter cake are washed with ice water,
0.81g product 12a is obtained after drying, is white solid, is directly thrown in next step.
(2) N- (2- ((2- aminophenyl) amino) -2- oxoethyl) -4- ((4- ((2,3- dimethyl -2H- indazole -6-
Base) (methyl) amino) pyrimidine -2-base) amino) benzamide (14a) preparation
It is added to intermediate 12a 1g in the anhydrous n,N-Dimethylformamide of 100mL, under ice bath, O- benzo three is added
After activating 30min, adjacent benzene is then added in nitrogen azoles-N, N, N', N'- tetramethylurea tetrafluoro boric acid 0.86g and triethylamine 0.45g
Diamines 0.29g, overnight, ethyl acetate dilution is added in reaction after the reaction was completed at room temperature, and n,N-Dimethylformamide is removed in washing,
Ethyl acetate layer saturated sodium bicarbonate solution and saturation NaCl solution are washed, and anhydrous magnesium sulfate is dry, and solvent is removed under reduced pressure, residual
Slag methylene chloride: methanol=30:1 volume ratio eluant, eluent carries out column chromatographic purifying and obtains 0.47g product 14a, pale yellow colored solid
Body.
(4) using p-nitrophenol as starting material, nucleophilic substitution occurs with the bromine alkanoic acid methyl esters of different chain length and obtains
Intermediate 16, intermediate 16 restore to obtain intermediate 17 through Pd/C, and intermediate 17 and compound 3 occur necleophilic reaction and obtain centre
Body 18, intermediate 18 obtain final product 19 through the ammonolysis reaction of ester.
Reaction equation is as follows:
Wherein n is 1~7.
Reagent and condition in above-mentioned reaction: (a) different chain length bromine alkanoic acid methyl esters, potassium carbonate, acetone flow back, overnight;
(b) Pd/C, methanol, hydrogen, room temperature, overnight;(c) isopropanol, concentrated hydrochloric acid flow back, overnight;(d) hydroxylamine hydrochloride, potassium hydroxide,
Anhydrous methanol, room temperature, 2h.
The bromine alkanoic acid methyl esters of the different chain length is: 2- methyl bromoacetate, 3- methyl bromide c, 4- bromo butyric acid methyl ester,
5- bromo pentane acid A ester, 6- bromocaproic acid methyl esters, 7- bromine methyl heptanoate or 8- bromine methyl caprylate.
Preferred according to the present invention, specific preparation process is as follows:
7- (4- ((4- ((2,3- dimethyl -2H- indazole -6- base) (methyl) amino) pyrimidine -2-base) amino) phenoxy group) -
The preparation of N- hydroxyl heptamide (19f), steps are as follows:
(1) preparation of methyl 7- (4-nitrophenoxy) heptanoate (16f)
P-nitrophenol 1.00g, 7- bromine methyl heptanoate 1.93g and potassium carbonate 2.98g are added in 50mL acetone, heated up
To reflux, overnight, after reaction, evaporating solvent under reduced pressure obtains 1.62g product 16f with re-crystallizing in ethyl acetate for reaction, for Huang
Color solid.
(2) preparation of methyl 7- (4- amino-benzene oxygen) heptanoate (17f)
Intermediate 16f 1.00g is added in 50mL methanol, 10%Pd/C 0.1g is added, is passed through hydrogen under atmospheric agitation
Gas, overnight in room temperature reaction, filtering, filter residue are washed with methanol, merging filtrate and washing lotion, evaporating solvent under reduced pressure, obtain 0.79g production
Object 17f is light tan solid.
(3) methyl 7- (4- ((4- ((2,3- dimethyl -2H- indazole -6- base) (methyl) amino) pyrimidine -2-base) amino)
Phenoxy group)-heptanoate (18f) preparation
By 3 0.5g of intermediate, intermediate 17f 0.52g and 0.5mL concentrated hydrochloric acid is added to 50mL isopropanol at room temperature
In, it is warming up to reflux, reaction is overnight.After reaction, evaporating solvent under reduced pressure, residue methylene chloride: methanol=40:1 volume
The eluant, eluent of ratio carries out column chromatographic purifying and obtains 0.61g product 18f, is white solid.
(4) 7- (4- ((4- ((2,3- dimethyl -2H- indazole -6- base) (methyl) amino) pyrimidine -2-base) amino) benzene oxygen
Base)-N- hydroxyl heptamide (19f) preparation
KOH 28.0g and hydroxylamine hydrochloride 23.53g are dissolved in respectively in 70mL and 120mL anhydrous methanol, obtain solution A and molten
Liquid B.Under ice bath, solution A is added dropwise in solution B, after stirring 2h, filters out precipitating, obtained filtrate is azanol potassium
Methanol solution.Compound 18f 0.30g is dissolved in 30mL azanol potassium solution, after 2h is stirred at room temperature, is concentrated under reduced pressure and is removed major part
Solvent, residual residue adjust pH to 5-6 with 1M HCl, and white solid, filtering is precipitated, and dry cake obtains 0.20g product 19f,
For white solid.
(5) it is starting material with intermediate 3, nucleophilic substitution occurs with paranitroanilinum and obtains intermediate 20, it is intermediate
Body 20 is reduced to intermediate 21 through Pd/C, and the docosandioic acid mono-methyl generation of intermediate 21 and different chain length is amide condensed to obtain centre
Body 22, the ammonolysis reaction that ester occurs for intermediate 22 obtain final product 23.
Reaction equation is as follows:
Wherein n is 1~7.
The reagent and condition of above-mentioned reaction: (a) paranitroanilinum, isopropanol, concentrated hydrochloric acid flow back, overnight;(b) Pd/C, first
Alcohol, hydrogen, room temperature, overnight;(c) the docosandioic acid mono-methyl of different chain length, O- benzotriazole-N, N, N', N'- tetramethylurea four
Fluoboric acid, triethylamine, N ' dinethylformamide, room temperature, overnight;(d) hydroxylamine hydrochloride, potassium hydroxide, anhydrous methanol, room temperature,
2h。
The docosandioic acid mono-methyl of the different chain length is: malonic acid monomethyl ester, monomethyl succinate, glutaric acid list first
Ester, adipic acid monomethyl ester, pimelic acid mono-methyl, suberic acid mono-methyl or monomethyl azelate.
Preferred according to the present invention, specific preparation process is as follows:
N1(4- ((4- ((2,3- dimethyl -2H- indazole -6- base) (methyl) amino) pyrimidine -2-base) amino) phenyl) -
N8The preparation of hydroxyl suberamide (23f), steps are as follows:
(1)N4(2,3- dimethyl -2H- indazole -6- base)-N4Methyl-N2(4- nitrobenzophenone) pyrimidine -2,4- diamines
(20) preparation
By 3 1.00g of intermediate, paranitroanilinum 0.58g and 0.5mL concentrated hydrochloric acid is added in 70mL isopropanol, heating
To reflux, reaction overnight, after reaction, is cooled to room temperature, and is filtered, and filter cake is washed with a small amount of isopropanol, and dry cake obtains
1.08g product 20 is faint yellow solid.
(2)N2(4- aminophenyl)-N4(2,3- dimethyl -2H- indazole -6- base)-N4Methylpyrimidine -2,4- diamines
(21) preparation
20 1.00g of intermediate is suspended in 70mL methanol, 0.1g 10%Pd/C is added, is passed through hydrogen under atmospheric agitation
Gas, overnight, after reaction, evaporating solvent under reduced pressure, residue with ethyl acetate is recrystallized to give 0.78g product 21 for room temperature reaction,
For light tan solid.
(3) methyl 8- ((4- ((4- ((2,3- dimethyl -2H- indazole -6- base) (methyl) amino) pyrimidine -2-base) amino)
Phenyl) amino) -8- oxo monooctyl ester (22f) preparation
Suberic acid mono-methyl 0.33g is added in the anhydrous n,N-Dimethylformamide of 50mL, O- benzo is added under ice bath
Triazole-N, N, N', N'- tetramethylurea tetrafluoro boric acid 0.68g and triethylamine 0.36g, finish, 30min are activated under ice bath, activation
After, 21 0.76g of intermediate is added, removes ice bath, overnight, ethyl acetate dilution, water is added in room temperature reaction after the reaction was completed
Remove n,N-Dimethylformamide, ethyl acetate layer saturated sodium bicarbonate solution and saturation NaCl solution are washed, anhydrous sulphur
Sour magnesium is dry, and evaporating solvent under reduced pressure, residue methylene chloride: methanol=30:1 volume ratio eluant, eluent carries out column chromatographic purifying and obtains
It is white solid to 0.37g product 22.
(4)N1(4- ((4- ((2,3- dimethyl -2H- indazole -6- base) (methyl) amino) pyrimidine -2-base) amino) benzene
Base)-N8The preparation of hydroxyl suberamide (23f)
KOH 28.0g and hydroxylamine hydrochloride 23.53g are dissolved in respectively in 70mL and 120mL anhydrous methanol, obtain solution A and molten
Liquid B.Under ice bath, solution A is added dropwise in solution B, after stirring 2h, filters out precipitating, obtained filtrate is azanol potassium
Methanol solution.Compound 22f 0.20g is dissolved in 30mL azanol potassium solution, after 2h is stirred at room temperature, is concentrated under reduced pressure and is removed major part
Solvent, residual residue adjust pH to 5-6 with 1M HCl, and white solid, filtering is precipitated, and dry cake obtains 0.14g product 23f,
For white solid.
(6) using p-fluoronitrobenzene as starting material, nucleophilic substitution occurs with the aminoalkyl methyl esters of different chain length and obtains
To intermediate 25, intermediate 25 restores to obtain intermediate 26 through Pd/C, and intermediate 26 occurs nucleophilic substitution with intermediate 3 and obtains
To intermediate 27, intermediate 27 obtains intermediate 28 through the ammonolysis reaction of ester.
Reaction equation is as follows:
Wherein n is 1~7.
The reagent and condition of reaction: (a) the aminoalkyl methyl esters of different chain length, potassium carbonate, n,N-Dimethylformamide, 50
DEG C, overnight;(b) Pd/C, hydrogen, methanol, overnight;(c) concentrated hydrochloric acid, isopropanol flow back, overnight;(d) hydroxylamine hydrochloride, hydroxide
Potassium, anhydrous methanol, room temperature, 2h.
The aminoalkyl methyl esters of the different chain length is: glycine methyl ester, 3- aminopropanoate, 4-Aminobutanoicacid first
Ester, 5- aminopentanoic acid methyl ester, 6-aminocaprolc acid methyl esters, 7- aminoheptylic acid methyl esters or 8- aminocaprylic acid methyl esters.
Preferred according to the present invention, specific preparation process is as follows:
6- ((4- ((4- ((2,3- dimethyl -2H- indazole -6- base) (methyl) amino) pyrimidine -2-base) amino) phenyl) ammonia
Base)-N- hydroxyl amide (28e) preparation, steps are as follows:
(1) preparation of methyl 6- ((4- nitrobenzophenone) amino) ester (25e)
P-fluoronitrobenzene 1.00g, 6-aminocaprolc acid methyl ester hydrochloride 1.54g and potassium carbonate 2.94g are added to 50mL N,
In dinethylformamide, 50 DEG C are warming up to, overnight, after reaction, is cooled to room temperature, reaction solution is poured into ice water, is analysed
Yellow solid out filters, and drying, residue petroleum ether: ethyl acetate=4:1 volume ratio eluant, eluent carries out column and chromatographs to obtain
1.32g product 25e is faint yellow solid.
(2) preparation of methyl 6- ((4- aminophenyl) amino) ester (26e)
It is suspended in intermediate 25e 1.00g in 70mL methanol, 10%Pd/C 0.1g is added, is passed through hydrogen under atmospheric agitation
Gas, overnight, after reaction, evaporating solvent under reduced pressure, residue with ethyl acetate is recrystallized to give 0.71g product 26e for room temperature reaction,
For brown solid.
(3) methyl 6- ((4- ((4- ((2,3- dimethyl -2H- indazole -6- base) (methyl) amino) pyrimidine -2-base) amino)
Phenyl) amino)-own ester (27e) preparation
By 3 0.50g of intermediate, intermediate 26e 0.49g and 0.5mL concentrated hydrochloric acid is added to 50mL isopropanol at room temperature
In, it is warming up to reflux, reaction is overnight.After reaction, evaporating solvent under reduced pressure, residue methylene chloride: methanol=40:1 volume
The eluant, eluent of ratio carries out column chromatographic purifying and obtains 0.55g product 27e, is faint yellow solid.
(4) 6- ((4- ((4- ((2,3- dimethyl -2H- indazole -6- base) (methyl) amino) pyrimidine -2-base) amino) benzene
Base) amino)-N- hydroxyl amide (28e) preparation
KOH 28.0g and hydroxylamine hydrochloride 23.53g are dissolved in respectively in 70mL and 120mL anhydrous methanol, obtain solution A and molten
Liquid B.Under ice bath, solution A is added dropwise in solution B, after stirring 2h, filters out precipitating, obtained filtrate is azanol potassium
Methanol solution.Compound 27e 0.20g is dissolved in 30mL azanol potassium solution, after 2h is stirred at room temperature, is concentrated under reduced pressure and is removed major part
Solvent, residual residue adjust pH to 5-6 with 1M HCl, and white solid, filtering is precipitated, and dry cake obtains 0.13g product 28e,
For light red solid.
The structural formula of target compound is as follows:
The specific preparation step of the compound will be described in detail in embodiment.
Those skilled in the art can optimize above-mentioned steps to improve yield, they can be according to the basic of this field
Knowledge works out synthetic route, such as selects reactant, solvent and temperature, can be by using various blocking groups to avoid side reaction
Occur to improve yield.These conventional guard methods can be found in T.Greene, Protecting Groups in
Organic Synthesis。
Detailed description of the invention
Term and definition meaning used herein is as follows:
ACHN cell is people's renal cell adenocarcinoma cell, and ags cell is human gastric adenocarcinoma, and hel cell is people's red white corpuscle
Leukaemia cell, HeLa cell are human cervical carcinoma cell, and HT-1080 cell is human fibrosarcoma cell, and HT-29 cell, which is behaved, to be tied
Colon-cancer cell, K562 cell are human chronic polymorpho nuclear leukemia cells, and KG1 cell is people's acute myeloid leukemia cell, MDA-
MB-231 is human breast cancer cell, and MOLT-4 is people's acute lymphoblastic leukemia cell, and PC-3 cell is human prostata cancer
Cell and HUVEC cell Human umbilical vein endothelial cells.
Three, the application of the bis- target spot inhibitor of HDAC and VEGFR based on pazopanib structure
The present invention also provides based on pazopanib structure HDAC and the bis- target spot inhibitor compounds of VEGFR preparation prevent
Or the application in treatment and tumor-related illness drug.
The tumor-related illness includes all kinds of blood tumors and all kinds of solid tumors.
All kinds of blood tumors include: each quasi-leukemia, myelosis tumor.For example serious urgency of various types of leukaemia
Property lymphocytic leukemia, acute myeloid leukaemia, acute megakaryocytic leukemia etc..Myelosis tumor includes that chronic Myelogenous is white
Blood disease, polycythemia vera, primary thrombocytosis, myelofibrosis, chronic neutrophilic leukemia, chronic acidophilus
Property granulocytic leukemia, systemic mastocytosis and other non-classified myelosis tumors.
The solid tumor include: various forms of nasopharyngeal carcinoma, clear-cell carcinoma, soft tissue sarcoma, thyroid papillary carcinoma,
Thymoma, liver cancer, breast cancer, melanoma, prostate cancer, retinoblastoma etc..
It is a kind of prevention or treatment with tumor-related illness pharmaceutical composition, comprising it is of the present invention be based on pazopanib knot
The bis- target spot inhibitor of the HDAC and VEGFR of structure or its pharmaceutically acceptable salt and one or more pharmaceutically acceptable carriers
Or excipient.
Detailed description of the invention
Western Blot experimental result of Fig. 1 compound 6d and 13f after HeLa cell handles 4h;
Fig. 2 compound 6d and 13f inhibit HUVECs segment dislocation experimental result;
Fig. 3 compound 6d and 13f inhibit rat chest aorta ring at blood vessel experimental result;
Fig. 4 nude mouse tumor photo;
Fig. 5 various dose compound 6d and 13f inhibition rate of tumor growth.
Specific embodiment
Below with reference to example, the present invention is described further, but not limited to this.
Embodiment 1: the synthesis of compound 6a-6c, by taking 6a as an example.
(1) preparation of N- (2- chlorine pyrimidine-4-yl) -2,3- dimethyl -6- amino -2H- indazole (2)
2,3- dimethyl -6- amino -2H- indazole 5.00g, 2,4- dichloro pyrimidine 13.9g and sodium bicarbonate 10.4g is molten
In 100mL dehydrated alcohol, 79 DEG C are heated to, flows back after 4h, cools down to room temperature, is filtered, filter cake is sufficiently washed with ethyl acetate
It washs, collects filtrate, be concentrated under reduced pressure, remove solvent, pale solid is obtained by filtration after being sufficiently beaten with ethyl acetate, with methanol weight
7.64g product 2 is obtained after crystallization, is white solid, yield: 90.0%;Mp:215-216℃.1H NMR(300MHz,DMSO-d6)δ
9.99 (s, 1H), 8.15 (d, J=5.9Hz, 1H), 7.94 (s, 1H), 7.63 (dd, J=0.8,8.9Hz, 1H), 6.98 (dd, J
=1.8,8.9Hz, 1H), 6.77 (d, J=5.9Hz, 1H), 4.01 (s, 3H), 2.58 (s, 3H).
(2) N- (2- chlorine pyrimidine-4-yl)-N, the preparation of 2,3- trimethyl -2H- indazole -6- amine (3)
Previous step product 2 1.00g and cesium carbonate 2.40g are added in 50mL n,N-Dimethylformamide, room temperature is anti-
20min is answered, iodomethane 0.78g is then slowly added into, finishes, 2h is reacted at room temperature, reaction solution is poured into ice water, is precipitated immediately big
Measure faint yellow solid, filtering, after drying, obtain 1.06g product 3 with re-crystallizing in ethyl acetate, be light yellow crystal, yield:
80.0%;Mp:173-174℃.1H NMR(400MHz,DMSO-d6) δ 7.95 (d, J=6.1Hz, 1H), 7.80 (dd, J=0.8,
8.7Hz, 1H), 7.51 (dd, J=0.8,1.8Hz, 1H), 6.88 (dd, J=1.8,8.8Hz, 1H), 6.24 (d, J=6.1Hz,
1H),4.06(s,3H),3.42(s,3H),2.63(s,3H)。
(3) 4- ((4- ((2,3- dimethyl -2H- indazole -6- base) (methyl) amino) pyrimidine -2-base) amino) benzoic acid
The preparation of (4a)
It disperses intermediate 3 0.50g and p-aminobenzoic acid 0.36g in 30mL isopropanol, 2 drop concentrated hydrochloric acids is added, add
To 85 DEG C, back flow reaction 4h is cooled to room temperature heat, and filtering washs filter cake with isopropanol and ethyl acetate, is dried to obtain 0.53g
Product 4a is white solid, yield: 80%;Mp:>250℃.1H NMR(400MHz,DMSO-d6)δ12.16(s,1H),9.80
(s, 1H), 7.91 (d, J=6.3Hz, 1H), 7.79 (d, J=8.7Hz, 3H), 7.74 (d, J=8.6Hz, 2H), 7.49 (d, J=
1.7Hz, 1H), 6.91 (dd, J=1.8,8.8Hz, 1H), 5.94 (d, J=6.2Hz, 1H), 4.08 (s, 3H), 3.51 (s, 3H),
2.64(s,3H).ESI-MS m/z:387.5[M-H]-。
(4) methyl 4- ((4- ((2,3- dimethyl -2H- indazole -6- base) (methyl) amino) pyrimidine -2-base) amino) benzene first
The preparation of acid esters (5a)
4a 0.50g is added in 50mL anhydrous methanol, 0.60g thionyl chloride is then added dropwise at 0 DEG C, finishes,
It after keeping the temperature 30min, is heated to flowing back after removing ice bath, after reacting 5h, solvent under reduced pressure be steamed, crude product recrystallisation from isopropanol
0.50g product 5a is obtained, is white solid, yield: 96%;Mp:198-200℃.1H NMR(400MHz,DMSO-d6)δ9.63
(s, 1H), 7.92 (d, J=6.0Hz, 1H), 7.83 (d, J=8.6Hz, 2H), 7.78 (d, J=8.6Hz, 1H), 7.72 (d, J=
8.6Hz, 2H), 7.46 (dd, J=0.8,1.7Hz, 1H), 6.89 (dd, J=1.8,8.8Hz, 1H), 5.91 (d, J=6.0Hz,
1H),4.07(s,3H),3.80(s,3H),3.49(s,3H),2.64(s,3H).ESI-MS m/z:403.5[M+H]+。
(5) 4- ((4- ((2,3- dimethyl -2H- indazole -6- base) (methyl) amino) pyrimidine -2-base) amino)-N- hydroxyl
The preparation of benzamide (6a)
KOH 28.0g and hydroxylamine hydrochloride 23.53g are dissolved in respectively in 70mL and 120mL anhydrous methanol, obtain solution A and molten
Liquid B.Under ice bath, solution A is added dropwise in solution B, after stirring 2h, filters out precipitating, obtained filtrate is azanol potassium
Methanol solution.Compound 5a 0.20g is dissolved in 30mL azanol potassium solution, and after 2h is stirred at room temperature, it is most of molten that removing is concentrated under reduced pressure
Agent, residual residue adjust pH to 5-6 with 1M HCl, and white solid, filtering is precipitated, and dry cake obtains 80.6mg product 6a, is
White solid, yield: 40%;Mp:210-212℃.1H NMR(400MHz,DMSO-d6)δ10.99(s,1H),9.49(s,1H),
8.85 (s, 1H), 7.89 (d, J=6.1Hz, 1H), 7.84-7.70 (m, 3H), 7.59 (d, J=8.3Hz, 2H), 7.46 (s,
1H), 6.90 (d, J=8.7Hz, 1H), 5.86 (d, J=6.2Hz, 1H), 4.07 (s, 3H), 3.49 (s, 3H), 2.64 (s, 3H)
.HRMS(AP-ESI)m/z calcd for C21H21N7O2[M+H]+404.1757,found 404.1739.Embodiment 2: chemical combination
The synthesis of object 6d-6e, by taking 6d as an example
(1) N- (2- aminophenyl) -4- ((4- ((2,3- dimethyl -2H- indazole -6- base) (methyl) amino) pyrimidine -2-
Base) amino) benzamide (6d) preparation
Intermediate 4a 0.50g is added in the anhydrous n,N-Dimethylformamide of 50mL, under ice bath, O- benzo three is added
After activating 30min, adjacent benzene is then added in nitrogen azoles-N, N, N', N'- tetramethylurea tetrafluoro boric acid 0.49g and triethylamine 0.26g
Diamines 0.17g, overnight, ethyl acetate dilution is added in reaction after the reaction was completed at room temperature, and n,N-Dimethylformamide is removed in washing,
Ethyl acetate layer saturated sodium bicarbonate solution and saturation NaCl solution are washed, and anhydrous magnesium sulfate is dry, and solvent is removed under reduced pressure, residual
Slag methylene chloride: methanol=30:1 volume ratio eluant, eluent carries out column chromatographic purifying and obtains 0.40g product 6d, solid for canescence
Body, yield: 65%;Mp:138-140℃.1H NMR(400MHz,DMSO-d6)δ9.54(s,1H),9.49(s,1H),7.91(d,
J=6.0Hz, 1H), 7.87 (d, J=9.0Hz, 2H), 7.83 (d, J=8.8Hz, 2H), 7.80-7.76 (m, 1H), 7.47 (d, J
=2.3Hz, 1H), 7.17 (dd, J=1.5,7.9Hz, 1H), 6.96 (td, J=1.6,7.6Hz, 1H), 6.91 (dd, J=1.8,
8.8Hz, 1H), 6.79 (dd, J=1.5,8.0Hz, 1H), 6.60 (td, J=1.5,7.5Hz, 1H), 5.87 (d, J=6.0Hz,
1H),4.89(s,2H),4.06(s,3H),3.51(s,3H),2.63(s,3H).HRMS(AP-ESI)m/z calcd for
C21H21N7O2[M+H]+ 479.2230,found 479.2257。
Embodiment 3: the synthesis of compound 10a-10b, by taking 10a as an example
(1) 4- ((4- ((2,3- dimethyl -2H- indazole -6- base) (methyl) amino) pyrimidine -2-base) amino)-N- methoxy
The preparation of base-N-methyl-benzamide (7a)
Intermediate 4a 1.00g is added in anhydrous n,N-Dimethylformamide, under ice bath, O- benzotriazole-is added
Then N, O- dimethyl is added after activating 30min in N, N, N', N'- tetramethylurea tetrafluoro boric acid 0.98g and triethylamine 0.52g
Hydroxylamine hydrochloride 0.30g and triethylamine 0.31g, overnight, ethyl acetate dilution is added in reaction after the reaction was completed at room temperature, and washing is removed
N,N-Dimethylformamide, ethyl acetate layer saturated sodium bicarbonate solution and saturation NaCl solution are washed, and anhydrous magnesium sulfate is dry
Dry, solvent is removed under reduced pressure, residue methylene chloride: methanol=35:1 volume ratio eluant, eluent carries out column chromatographic purifying and obtains
0.78g product 7a is white solid, yield 70%;Mp:216-218℃.1H NMR(400MHz,DMSO-d6)δ9.46(s,
1H), 7.90 (d, J=6.0Hz, 1H), 7.82-7.74 (m, 3H), 7.48 (d, J=8.6Hz, 2H), 7.46 (d, J=1.4Hz,
1H), 6.89 (dd, J=1.8,8.8Hz, 1H), 5.87 (d, J=6.0Hz, 1H), 4.06 (s, 3H), 3.55 (s, 3H), 3.48
(s,3H),3.23(s,3H),2.63(s,3H)。
(2) 4- ((4- ((2,3- dimethyl -2H- indazole -6- base) (methyl) amino) pyrimidine -2-base) amino) benzaldehyde
The preparation of (8a)
Compound 7a 1.00g is dissolved in 50mL anhydrous tetrahydro furan, and is cooled to -40 DEG C in low-temp reaction instrument.To
It is slowly added to tetrahydrochysene lithium aluminium 0.26g in batches, this thermotonus 2h is maintained slowly carefully to be quenched after reaction with ice water
Reaction is to there is no bubble generations.Reaction solution is diluted with water, and is extracted with ethyl acetate, and merges organic layer, and saturation NaCl solution is washed
It washs, anhydrous magnesium sulfate is dry, solvent is concentrated under reduced pressure, residue methylene chloride: methanol=40:1 volume ratio eluant, eluent carries out column
Chromatographic purifying obtains 0.61g product 8a, is white solid, yield: 70%;Mp:242-244℃.1H NMR(400MHz,DMSO-
d6) δ 9.77 (d, J=4.6Hz, 2H), 7.96-7.93 (m, 3H), 7.78 (d, J=8.7Hz, 1H), 7.69 (d, J=8.4Hz,
2H), 7.47 (d, J=1.6Hz, 1H), 6.90 (dd, J=1.8,8.8Hz, 1H), 5.92 (d, J=6.0Hz, 1H), 4.07 (s,
3H),3.50(s,3H),2.64(s,3H)。
(3) ethyl (E) -3- (4- ((4- ((2,3- dimethyl -2H- indazole -6- base) (methyl) amino) pyrimidine -2-base) ammonia
Base) phenyl) acrylate (9a) preparation
Phosphonoacetate 0.32g is added into 50mL anhydrous tetrahydro furan, is cooled to -5-0 DEG C, is slowly added to
NaH0.16g is finished, and stirs 20min, and the tetrahydrofuran solution of 8a 0.52g is then added dropwise, and room temperature reaction is stayed overnight, end of reaction
Afterwards, 10% ammonium chloride solution of 50mL is added, stirs stratification after 30min, after organic phase is dry, filtering is concentrated to get thick
Product.Residue methylene chloride: methanol=40:1 volume ratio eluant, eluent carries out column chromatographic purifying and obtains 0.48g product 9a, is white
Color solid, yield: 48%;Mp:195-197℃.1H NMR(400MHz,DMSO-d6) δ 9.50 (s, 1H), 7.89 (d, J=
6.0Hz, 1H), 7.83 (d, J=8.7Hz, 2H), 7.78 (dd, J=0.8,8.7Hz, 1H), 7.58-7.51 (m, 3H), 7.46
(dd, J=0.8,1.8Hz, 1H), 6.90 (dd, J=1.8,8.8Hz, 1H), 6.42 (d, J=16.0Hz, 1H), 5.84 (d, J=
6.0Hz, 1H), 4.17 (q, J=7.1Hz, 2H), 4.07 (s, 3H), 3.49 (s, 3H), 2.64 (s, 3H), 1.25 (t, J=
7.1Hz,3H).(4) (E) -3- (4- ((4- ((2,3- dimethyl -2H- indazole -6- base) (methyl) amino) pyrimidine -2-base) ammonia
Base) phenyl)-N- hydroxyacrylamide (10a) preparation
KOH 28.0g and hydroxylamine hydrochloride 23.53g are dissolved in respectively in 70mL and 120mL anhydrous methanol, obtain solution A and molten
Liquid B.Under ice bath, solution A is added dropwise in solution B, after stirring 2h, filters out precipitating, obtained filtrate is azanol potassium
Methanol solution.Compound 9a 0.50g is dissolved in 30mL azanol potassium solution, and after 2h is stirred at room temperature, it is most of molten that removing is concentrated under reduced pressure
Agent, residual residue adjust pH to 5-6 with 1M HCl, and white solid, filtering is precipitated, and dry cake obtains 0.29g product 10a, is
White solid, yield: 60%;Mp:194-196℃.1H NMR(400MHz,DMSO-d6)δ10.65(s,1H),9.42(s,1H),
8.96 (s, 1H), 7.88 (d, J=5.9Hz, 1H), 7.81 (d, J=8.3Hz, 2H), 7.77 (d, J=8.8Hz, 1H), 7.46
(s, 1H), 7.43-7.32 (m, 3H), 6.95-6.83 (m, 1H), 6.28 (d, J=15.7Hz, 1H), 5.83 (d, J=6.1Hz,
1H),4.07(s,3H),3.49(s,3H),2.64(s,3H).HRMS(AP-ESI)m/z calcd for C23H23N7O2[M+H]+
430.1991,found 430.1988。
Embodiment 4: the synthesis of compound 13a-13i, by taking 13a as an example
(1) methyl (4- ((2,3- dimethyl -2H- indazole -6- base) (methyl) amino) pyrimidine -2-base) amino) benzoyl
Base) glycinate (11a) preparation
Intermediate 4a 1.00g is added in the anhydrous n,N-Dimethylformamide of 100mL, under ice bath, O- benzo three is added
Then sweet ammonia is added after activating 30min in nitrogen azoles-N, N, N', N'- tetramethylurea tetrafluoro boric acid 0.98g and triethylamine 0.52g
Acid methyl ester hydrochloride salt 0.39g, overnight, ethyl acetate dilution is added in reaction after the reaction was completed at room temperature, and N, N- diformazan are removed in washing
Base formamide, ethyl acetate layer saturated sodium bicarbonate solution and saturation NaCl solution are washed, and anhydrous magnesium sulfate is dry, and decompression removes
Remove solvent, residue methylene chloride: methanol=30:1 volume ratio eluant, eluent carries out column chromatographic purifying and obtains 0.87g product 11a,
For white solid, yield 74%;Mp:170-172℃.1H NMR(400MHz,DMSO-d6)δ9.51(s,1H),8.72(t,J
=5.9Hz, 1H), 7.90 (d, J=6.0Hz, 1H), 7.84 (d, J=8.6Hz, 2H), 7.77 (d, J=8.7Hz, 1H), 7.71
(d, J=8.5Hz, 2H), 7.46 (d, J=1.7Hz, 1H), 6.90 (dd, J=1.8,8.8Hz, 1H), 5.85 (d, J=6.1Hz,
1H), 4.07 (s, 3H), 3.98 (d, J=5.8Hz, 2H), 3.65 (s, 3H), 3.50 (s, 3H), 2.64 (s, 3H).
(2) 4- ((4- ((2,3- dimethyl -2H- indazole -6- base) (methyl) amino) pyrimidine -2-base) amino)-N- (2-
(azanol) -2- oxoethyl) benzamide (13a) preparation
KOH 28.0g and hydroxylamine hydrochloride 23.53g are dissolved in respectively in 70mL and 120mL anhydrous methanol, obtain solution A and molten
Liquid B.Under ice bath, solution A is added dropwise in solution B, after stirring 2h, filters out precipitating, obtained filtrate is azanol potassium
Methanol solution.Compound 11a (0.50g, 1.09mmol) is dissolved in 30mL azanol potassium solution, after 2h is stirred at room temperature, is concentrated under reduced pressure
Most of solvent is removed, residual residue adjusts pH to 5-6 with 1M HCl, and white solid, filtering is precipitated, and dry cake is produced
Object 13a, for white solid (0.31g, yield 61%), Mp:216-218 DEG C of1H NMR(400MHz,DMSO-d6)δ10.53
(s, 1H), 9.46 (s, 1H), 8.77 (s, 1H), 8.45 (s, 1H), 7.89 (d, J=5.9Hz, 1H), 7.82 (d, J=8.5Hz,
2H), 7.77 (d, J=8.7Hz, 1H), 7.72 (d, J=8.4Hz, 2H), 7.46 (d, J=1.8Hz, 1H), 6.90 (dd, J=
1.8,8.8Hz, 1H), 5.85 (d, J=6.0Hz, 1H), 4.07 (s, 3H), 3.76 (d, J=5.8Hz, 2H), 3.49 (s, 3H),
2.64(s,3H).HRMS(AP-ESI)m/z calcd for C23H24N8O3[M-H]-459.1971,found 459.1921。
Embodiment 5: the synthesis of compound 14a-14g, by taking 14a as an example
(1) 4- ((4- ((2,3- dimethyl -2H- indazole -6- base) (methyl) amino) pyrimidine -2-base) amino) benzoyl
Base) glycine (12a) preparation
11a (1.00g, 2.18mmol) is added in 30mL methanol, 5mL 3M NaOH solution is then added, at room temperature
4h is stirred, after reaction, decompression boils off most of methanol, and residue adjusts pH to 5-6 with 1M HCl solution.Filtering, filter cake
It is washed with ice water, obtains product 12a after dry, be that (yield: 84%) 0.81g, Mp: > 250 DEG C, directly casts one to white solid
Walk1H NMR(400MHz,DMSO-d6)δ12.57(s,1H),10.69(s,1H),8.79(s,1H),8.01–7.61(m,6H),
7.59 (d, J=1.7Hz, 1H), 6.95 (dd, J=1.8,8.8Hz, 1H), 6.03 (s, 1H), 4.09 (s, 3H), 3.92 (d, J=
5.8Hz,2H),3.57(s,3H),2.66(s,3H)。
(2) N- (2- ((2- aminophenyl) amino) -2- oxoethyl) -4- ((4- ((2,3- dimethyl -2H- indazole -6-
Base) (methyl) amino) pyrimidine -2-base) amino) benzamide (14a) preparation
Intermediate 12a (1g, 2.24mmol) is added in anhydrous n,N-Dimethylformamide, under ice bath, O- benzene is added
And triazole-N, N, N', N'- tetramethylurea tetrafluoro boric acid (0.86g, 2.69mmol) and triethylamine (0.45g,
4.48mmol), after activating 30min, o-phenylenediamine (0.29g, 2.69mmol) then is added, reaction overnight, has been reacted at room temperature
Diluted at rear addition ethyl acetate, n,N-Dimethylformamide is removed in washing, ethyl acetate layer saturated sodium bicarbonate solution and
It is saturated NaCl solution washing, anhydrous magnesium sulfate is dry, solvent is removed under reduced pressure, residue methylene chloride: methanol=30:1 volume ratio
Eluant, eluent carry out column chromatographic purifying and obtain product 14a, faint yellow solid (0.47g, yield 39%), Mp:178-180 DEG C
.1H NMR(400MHz,DMSO-d6) δ 9.51 (s, 1H), 9.23 (s, 1H), 8.62 (t, J=5.8Hz, 1H), 7.90 (d, J=
6.1Hz, 1H), 7.83 (d, J=8.7Hz, 2H), 7.79-7.71 (m, 3H), 7.49-7.43 (m, 1H), 7.12 (d, J=
7.5Hz, 1H), 6.93-6.89 (m, 2H), 6.71 (dd, J=1.4,7.9Hz, 1H), 6.54 (t, J=7.5Hz, 1H), 5.86
(d, J=6.2Hz, 1H), 4.92 (s, 2H), 4.07 (s, 3H), 4.05-4.00 (m, 2H), 3.50 (s, 3H), 2.64 (s, 3H)
.HRMS(AP-ESI)m/z calcd for C29H29N9O2[M+H]+536.2444,found 536.2498。
Embodiment 6: the synthesis of compound 19a-19g, by taking 19f as an example
(1) preparation of methyl 7- (4-nitrophenoxy) heptanoate (16f)
P-nitrophenol 1.00g, 7- bromine methyl heptanoate 1.93g and potassium carbonate 2.98g are added in 50mL acetone, heated up
To reflux, overnight, after reaction, evaporating solvent under reduced pressure obtains 1.62g product 16f with re-crystallizing in ethyl acetate for reaction, for Huang
Color solid, yield: 80%;ESI-MS m/z:282.3[M+H]+。
(2) preparation of methyl 7- (4- amino-benzene oxygen) heptanoate (17f)
Intermediate 16f 1.00g is added in 50mL methanol, 10%Pd/C 0.1g is added, is passed through hydrogen under atmospheric agitation
Gas, overnight in room temperature reaction, filtering, filter residue are washed with methanol, merging filtrate and washing lotion, evaporating solvent under reduced pressure, obtain 0.79g production
Object 17f is light tan solid, yield: 88%;ESI-MS m/z:251.4[M+H]+, direct plunge into next step.
(3) methyl 7- (4- ((4- ((2,3- dimethyl -2H- indazole -6- base) (methyl) amino) pyrimidine -2-base) amino)
Phenoxy group)-heptanoate (18f) preparation
By 3 0.5g of intermediate, intermediate 17f 0.52g and 0.5mL concentrated hydrochloric acid is added to 50mL isopropanol at room temperature
In, it is warming up to reflux, reaction is overnight.After reaction, evaporating solvent under reduced pressure, residue methylene chloride: methanol=40:1 volume
The eluant, eluent of ratio carries out column chromatographic purifying, obtains 0.61g product 18f, is white solid, yield: 70%;ESI-MS m/z:
503.6[M+H]+。
(4) 7- (4- ((4- ((2,3- dimethyl -2H- indazole -6- base) (methyl) amino) pyrimidine -2-base) amino) benzene oxygen
Base)-N- hydroxyl heptamide (19f) preparation
KOH 28.0g and hydroxylamine hydrochloride 23.53g are dissolved in respectively in 70mL and 120mL anhydrous methanol, obtain solution A and molten
Liquid B.Under ice bath, solution A is added dropwise in solution B, after stirring 2h, filters out precipitating, obtained filtrate is azanol potassium
Methanol solution.Compound 18f 0.30g is dissolved in 30mL azanol potassium solution, after 2h is stirred at room temperature, is concentrated under reduced pressure and is removed major part
Solvent, residual residue adjust pH to 5-6 with 1M HCl, and white solid, filtering is precipitated, and dry cake obtains 0.20g product 19f,
For white solid, yield: 65%;1H NMR(400MHz,DMSO-d6) δ 10.33 (s, 1H), 8.93 (s, 1H), 8.65 (d, J=
1.8Hz, 1H), 7.80 (d, J=6.0Hz, 1H), 7.75 (dd, J=0.8,8.7Hz, 1H), 7.60 (d, J=8.9Hz, 2H),
7.42 (dd, J=0.8,1.8Hz, 1H), 6.87 (dd, J=1.8,8.8Hz, 1H), 6.75 (d, J=8.9Hz, 2H), 5.73 (d,
J=5.9Hz, 1H), 4.06 (s, 3H), 3.88 (t, J=6.5Hz, 2H), 3.45 (s, 3H), 2.63 (s, 3H), 2.02-1.90
(m, 2H), 1.67 (p, J=6.8Hz, 2H), 1.51 (p, J=7.4Hz, 2H), 1.39 (p, J=7.2Hz, 2H), 1.34-1.21
(m,2H).ESI-MS m/z:504.7[M+H]+。
Embodiment 7: the synthesis of compound 23a-23g, by taking compound 23f as an example
(1)N4(2,3- dimethyl -2H- indazole -6- base)-N4Methyl-N2(4- nitrobenzophenone) pyrimidine -2,4- diamines
(20) preparation
3 1.00g of intermediate, paranitroanilinum 0.58g and 0.5mL concentrated hydrochloric acid are added in 70mL isopropanol, heated up
To reflux, reaction overnight, after reaction, is cooled to room temperature, and is filtered, and filter cake is washed with a small amount of isopropanol, and dry cake obtains
1.08g product 20 is faint yellow solid, yield: 80%;1H NMR(400MHz,DMSO-d6)δ11.01(s,1H),8.08(s,
2H), 7.99 (d, J=7.0Hz, 1H), 7.87 (d, J=8.8Hz, 1H), 7.83 (s, 2H), 7.59 (d, J=1.8Hz, 1H),
6.95 (dd, J=1.8,8.7Hz, 1H), 6.17 (s, 1H), 4.10 (s, 3H), 3.58 (s, 3H), 2.67 (s, 3H).
(2)N2(4- aminophenyl)-N4(2,3- dimethyl -2H- indazole -6- base)-N4Methylpyrimidine -2,4- diamines
(21) preparation
20 1.00g of intermediate is suspended in 70mL methanol, 10%Pd/C 0.1g is added, is passed through hydrogen under atmospheric agitation
Gas, overnight, after reaction, evaporating solvent under reduced pressure, residue with ethyl acetate is recrystallized to give 0.78g product 21 for room temperature reaction,
For light tan solid, yield: 84%;ESI-MS m/z:360.4[M+H]+。
(3) methyl 8- ((4- ((4- ((2,3- dimethyl -2H- indazole -6- base) (methyl) amino) pyrimidine -2-base) amino)
Phenyl) amino) -8- oxo monooctyl ester (22f) preparation
Suberic acid mono-methyl 0.33g is added in the anhydrous n,N-Dimethylformamide of 50mL, O- benzo is added under ice bath
Triazole-N, N, N', N'- tetramethylurea tetrafluoro boric acid 0.68g and 0.36g triethylamine, finishes, 30min is activated under ice bath, activation
After, 21 0.76g of intermediate is added, removes ice bath, overnight, ethyl acetate dilution, water is added in room temperature reaction after the reaction was completed
Remove n,N-Dimethylformamide, ethyl acetate layer saturated sodium bicarbonate solution and saturation NaCl solution are washed, anhydrous sulphur
Sour magnesium is dry, and evaporating solvent under reduced pressure, residue methylene chloride: methanol=30:1 volume ratio eluant, eluent carries out column chromatographic purifying and obtains
It is white solid, yield: 40% to 0.37g product 22f;ESI-MS m/z:530.5[M+H]+。
(4)N1(4- ((4- ((2,3- dimethyl -2H- indazole -6- base) (methyl) amino) pyrimidine -2-base) amino) benzene
Base)-N8The preparation of hydroxyl suberamide (23f)
KOH 28.0g and hydroxylamine hydrochloride 23.53g are dissolved in respectively in 70mL and 120mL anhydrous methanol, obtain solution A and molten
Liquid B.Under ice bath, solution A is added dropwise in solution B, after stirring 2h, filters out precipitating, obtained filtrate is azanol potassium
Methanol solution.Compound 22f 0.20g is dissolved in 30mL azanol potassium solution, after 2h is stirred at room temperature, is concentrated under reduced pressure and is removed major part
Solvent, residual residue adjust pH to 5-6 with 1M HCl, and white solid, filtering is precipitated, and dry cake obtains 0.14g product 23f,
For white solid, yield: 70%;1H NMR(400MHz,DMSO-d6)δ10.34(s,1H),9.68(s,1H),9.04(s,1H),
8.65 (s, 1H), 7.82 (d, J=5.9Hz, 1H), 7.75 (d, J=8.8Hz, 1H), 7.64-7.56 (m, 2H), 7.43 (d, J=
1.7Hz, 1H), 7.37 (d, J=8.9Hz, 2H), 6.88 (dd, J=1.8,8.8Hz, 1H), 5.76 (d, J=6.0Hz, 1H),
4.06 (s, 3H), 3.46 (s, 3H), 2.63 (s, 3H), 2.25 (t, J=7.4Hz, 2H), 1.94 (t, J=7.4Hz, 2H),
1.64-1.40(m,4H),1.34-1.21(m,4H).ESI-MS m/z:531.6[M+H]+。
Embodiment 8: the synthesis of compound 28a-28g, by taking compound 28e as an example
(1) preparation of methyl 6- ((4- nitrobenzophenone) amino) ester (25e)
P-fluoronitrobenzene 1.00g, 6-aminocaprolc acid methyl ester hydrochloride 1.54g and potassium carbonate 2.94g are added to 50mL N,
In dinethylformamide, 50 DEG C are warming up to, overnight, after reaction, is cooled to room temperature, reaction solution is poured into ice water, is analysed
Yellow solid out filters, and drying, residue petroleum ether: ethyl acetate=4:1 volume ratio eluant, eluent carries out column and chromatographs to obtain
1.32g product 25e is faint yellow solid, yield: 70%;ESI-MS m/z:267.3[M+H]+。
(2) preparation of methyl 6- ((4- aminophenyl) amino) ester (26e)
Intermediate 25e 1.00g is suspended in 70mL methanol, 10%Pd/C 0.1g is added, is passed through hydrogen under atmospheric agitation
Gas, overnight, after reaction, evaporating solvent under reduced pressure, residue with ethyl acetate is recrystallized to give 0.71g product 26e for room temperature reaction,
For brown solid, yield: 80%;ESI-MS m/z:237.4[M+H]+。
(3) methyl 6- ((4- ((4- ((2,3- dimethyl -2H- indazole -6- base) (methyl) amino) pyrimidine -2-base) amino)
Phenyl) amino)-own ester (27e) preparation
By 3 0.5g of intermediate, intermediate 26e 0.49g and 0.5mL concentrated hydrochloric acid is added to 50mL isopropanol at room temperature
In, it is warming up to reflux, reaction is overnight.After reaction, evaporating solvent under reduced pressure, residue methylene chloride: methanol=40:1 volume
The eluant, eluent of ratio carries out column chromatographic purifying and obtains product 27e, is 0.55g faint yellow solid, yield: 65%;ESI-MS m/z:
488.6[M+H]+。
(4) 6- ((4- ((4- ((2,3- dimethyl -2H- indazole -6- base) (methyl) amino) pyrimidine -2-base) amino) benzene
Base) amino)-N- hydroxyl amide (28e) preparation
KOH 28.0g and hydroxylamine hydrochloride 23.53g are dissolved in respectively in 70mL and 120mL anhydrous methanol, obtain solution A and molten
Liquid B.Under ice bath, solution A is added dropwise in solution B, after stirring 2h, filters out precipitating, obtained filtrate is azanol potassium
Methanol solution.Compound 27e 0.20g is dissolved in 30mL azanol potassium solution, after 2h is stirred at room temperature, is concentrated under reduced pressure and is removed major part
Solvent, residual residue adjust pH to 5-6 with 1M HCl, and white solid, filtering is precipitated, and dry cake obtains 0.13g product 28e,
For light red solid, yield: 66%.1H NMR(400MHz,DMSO-d6)δ10.36(s,1H),8.78(s,1H),8.68(s,
1H), 7.76-7.73 (m, 2H), 7.43 (d, J=1.6Hz, 1H), 7.37 (d, J=8.4Hz, 2H), 6.87 (dd, J=1.8,
8.8Hz, 1H), 6.45 (d, J=8.4Hz, 2H), 5.68 (d, J=6.0Hz, 1H), 4.06 (s, 3H), 3.49 (s, 1H), 3.44
(s, 3H), 2.93 (t, J=7.0Hz, 2H), 1.96 (t, J=7.3Hz, 2H), 1.61-1.10 (m, 6H) .ESI-MS m/z:
489.3[M+H]+。
Embodiment 9: the external HDAC inhibitory activity test experiments of compound
HeLa nuclear extract that we have used convenience to be easy to get first (mainly containing HDAC1 and HDAC2) as HDAC enzyme source,
The external HDACs inhibitory activity of target compound is determined.
The external HDAC inhibitory activity of 1 compound of table
Experiment conclusion: majority of compounds has certain inhibiting effect to HDACs, in hydroxamic acid compound 13e and
The activity of 13f is best, hence it is evident that is better than positive control drug SAHA.The activity of 6d and 14e preferably, is lived in o-phenylenediamine class compound
Property is suitable with positive control drug MS275.
Embodiment 10: the external HDAC subtype-selective experiment of representative compound
The external HDAC subtype-selective of 2 representative compound of table
aUndetermined
Experiment conclusion: hydroxamic acid representative compound 10a is similar with positive control drug SAHA with 13f, is wide spectrum
Hdac inhibitor, but compound 13f is better than SAHA to the inhibitory activity of HDAC6.O-phenylenediamine class representative compound 6d and
14g is similar with positive control drug MS275, is Class I selectivity hdac inhibitor.
Embodiment 11: the external VEGFR-2 inhibitory activity measurement experiment of compound
All target compounds are determined first under 0.2 μM of concentration to the percent inhibition of VEGFR-2, and then further
Determine the IC of the external anti-VEGFR-2 of 4 representative compounds (10a, 13f, 6d, 14g)50Value.
The external VEGFR-2 inhibitory activity of 3 compound of table
aUndetermined
Experiment conclusion: majority of compounds 200nM show stronger VEGFR-2 inhibitory activity (inhibiting rate >
90%) it is comparable external that, representative compound 10a, 13f, 6d and 14g show positive control drug Pazapanib
VEGFR-2 inhibitory activity.
Embodiment 12: the immunoblot experiment of representative compound
In order to further study compound in the cell to the inhibiting effect of HDAC, it is real that We conducted Western Blot
Test, determine representative compound 6d and 13f to acetylated H4 (Class I HDAC substrate) and
The influence of acetylated tubulin (HDAC6 substrate) expression.Wherein SAHA, TubA and MS275 are positive
Comparison medicine, β-Actin are internal standards.Experimental result is referring to Fig. 1.
Experiment conclusion: compound 6d can significantly improve the level of acetylated histones H4 (Ac-HH4) at 1 μM, activity with
MS275 is suitable, but compound 6d cannot increase the level of acetylation tubulin (Ac-tubulin), shows that compound 6d is one
A Class I HDAC selective depressant.Compound 13f can significantly improve acetylation tubulin (Ac- in 100nM
Tubulin level), activity are better than TubA and SAHA;13f can also improve the water of acetylated histones H4 (Ac-HH4) simultaneously
It is flat, show that compound 13f is wide spectrum hdac inhibitor.
Embodiment 13: the extracorporeal anti-tumor cell-proliferation activity experiment of representative compound
We use the extracorporeal anti-tumor cell-proliferation activity that more commonly used MTT method determines test-compound.
The extracorporeal anti-tumor cell-proliferation activity of 4 representative compound of table
aUndetermined
Experiment conclusion: most compound shows certain anti-increasing to a variety of blood tumors and solid tumor cell system
Effect is grown, wherein compound 10a and 13f activity is optimal in hydroxamic acid compound, shows and positive control drug SAHA
Comparable anti-tumour cell proliferative activity.Compound 6d activity is optimal in o-phenylenediamine class compound, and it is right with the positive to show
According to the comparable anti-tumour cell proliferative activity of medicine MS275.
14 representative compound of embodiment inhibits Human umbilical vein endothelial cells to test at lumen of vessels
We have selected representative compound 6d and 13f, determine compound under 1 μM of concentration to HUVECs segment dislocation
Influence, and select Pazopanib as positive control drug.Experimental result is referring to fig. 2.
Experiment conclusion: representative compound 6d and 13f is shown and positive control drug Pazopanib under 1 μM of concentration
Comparable external anti-HUVECs is at lumen of vessels activity.
The rat chest aorta of 15 representative compound of embodiment is at vascular study activity experiment
Our further progresss rat chest aorta tests the external anti-angiogenic life of further assessment compound at blood vessel
It is Viability, influence of the representative compound 6d and 13f under 5 μM of concentration to rat chest aorta at blood vessel is determined, it is positive right
It is Pazopanib according to medicine.Experimental result is referring to Fig. 3.
Experiment conclusion: it is micro- that compound 6d, 13f and Pazopanib can almost completely inhibit arterial ring under 5 μM of concentration
The formation of blood vessel.
The internal anti-tumor activity of 16 representative compound of embodiment is tested
Based on compound 6d and 13f extracorporeal anti-tumor cell-proliferation activity excellent in HT-29 cell line, we are established
Nude mice by subcutaneous HT-29 lotus knurl model, uses SAHA and Pazopanib as positive control.Compound 6d and 13f are with 50mg/
Two dosages of kg/day and 100mg/kg/day, SAHA is with 100mg/kg/day and Pazopanib with 50mg/
Kg/day oral administration.Putting to death animal after administration 21 days terminates to test, and the tumour for calculating test-compound and positive control drug is raw
Long inhibiting rate (TGI) assesses the antitumor activity of compound in terms of volume and weight two of tumor.Experimental result referring to, figure
4, Fig. 5.
Experiment conclusion: compound 6d and 13f show anti-cancer activity in vivo, and wherein 6d activity is preferable.In 100mg/kg/
When day dosage, 6d activity be better than listing hdac inhibitor class drug SAHA, in 50mg/kg/day dosage, 6d activity with it is upper
VEGFR inhibitor class drug pazopanib in city is suitable, has very high follow-up study Development volue.
Claims (9)
1. the bis- target spot inhibitor of HDAC and VEGFR based on pazopanib structure, pharmaceutically acceptable salt, feature exist
In with structure shown in following general formula I, II or III:
Wherein
X is
N is 0~9;
Y is
2. the bis- target spot inhibitor of HDAC and VEGFR as described in claim 1 based on pazopanib structure, which is characterized in that
X is in the contraposition or meta position of phenyl ring in Y and II in general formula I;
X is
N is 0-7;
Y is
3. the bis- target spot inhibitor of HDAC and VEGFR as claimed in claim 1 or 2 based on pazopanib structure, feature exist
In compound is one of following:
4. the preparation method of the bis- target spot inhibitor of HDAC and VEGFR as described in claim 1 based on pazopanib structure, is
One of following method:
(1) with 2,3- dimethyl -6- amino -2H- indazole be starting material, under sodium bicarbonate alkaline condition with 2,4- dichloro
Pyrimidine occurs nucleophilic substitution and obtains intermediate 2, and intermediate 2 obtains intermediate with iodomethane reaction under cesium carbonate catalysis
3, intermediate 3 occurs nucleophilic substitution from different substituted aniline under concentrated hydrochloric acid catalysis and obtains intermediate 4a-4c, intermediate
4a-4c protects to obtain intermediate 5a-5c through methyl esters, and intermediate 5a-5c obtains final product 6a-6c through the ammonolysis reaction of ester;Furthermore
Intermediate 4a-4b and o-phenylenediamine obtain final product 6d-6e through amide condensed;
Reaction equation is as follows:
The phenyl ring of wherein 4a, 5a, 6a, 6d are that contraposition replaces, 4b, 5b, and the phenyl ring of 6b, 6e are that meta position replaces;
Reagent and condition in above-mentioned reaction equation: (a) 2,4- dichloro pyrimidine, sodium bicarbonate, dehydrated alcohol, reflux, 4h;(b) carbon
Sour caesium, iodomethane, n,N-Dimethylformamide, room temperature, 2h;(c) isopropanol, concentrated hydrochloric acid, reflux, 4h;(d) three nitrogen of O- benzo
Azoles-N, N, N ', N '-tetramethylurea tetrafluoro boric acid, triethylamine, o-phenylenediamine, n,N-Dimethylformamide, 0 DEG C-room temperature, overnight
(e) anhydrous methanol, thionyl chloride flow back, overnight;(f) hydroxylamine hydrochloride, potassium hydroxide, anhydrous methanol, room temperature, 2h;
The different aniline replaced are as follows: p-aminobenzoic acid, gavaculine or 5- amino-2-methyl benzoic acid;
(2) using intermediate 4a-4b as starting material, with N, the generation of O- dimethyl hydroxylamine hydrochloride is amide condensed to obtain intermediate 7a-
7b, intermediate 7a-7b are reduced to aldehyde intermediate 8a-8b through tetrahydrochysene lithium aluminium, and intermediate 8a-8b and phosphonoacetate occur
Huo Naer-Wordsworth-Ai Mengsi reaction response obtains intermediate 9a-9b, and intermediate 9a-9b obtains whole production through the ammonolysis of ester
Object 10a-10b;
Reaction equation is as follows:
The phenyl ring of wherein 4a, 7a, 8a, 9a, 10a are that contraposition replaces, 4b, 7b, 8b, 9b, and the phenyl ring of 10b is meta position substitution;
Reagent and condition in above-mentioned reaction equation: (a) N, O- dimethyl hydroxylamine hydrochloride, O- benzotriazole-N, N, N ', N '-four
Methylurea tetrafluoro boric acid, triethylamine, n,N-Dimethylformamide, room temperature, overnight;(b) tetrahydrochysene lithium aluminium, tetrahydrofuran, -20 DEG C,
4h;(c) phosphonoacetate, sodium hydride, tetrahydrofuran, 0 DEG C-room temperature, overnight;(d) hydroxylamine hydrochloride, potassium hydroxide, nothing
Water methanol, room temperature, 2h;
(3) using intermediate 4a-4c as starting material, the amino-alkane methyl esters of intermediate 4a-4c and different chain length is through amide condensed
Reaction obtains intermediate 11a-11i, and intermediate 11a-11i obtains final product 13a-13i through the ammonolysis reaction of ester;Intermediate 11a-
11h is hydrolyzed to intermediate 12a-12g under the conditions of Sodium Hydroxide Alkaline, and intermediate 12a-12g and o-phenylenediamine are through amide condensed
Reaction obtains final product 14a-14g;
Reaction equation is as follows:
The phenyl ring of wherein 4a, 11a-11g, 12a-12g, 13a-13g, 14a-14g are that contraposition replaces, and the phenyl ring of 4b, 11h, 13h are
Meta position replaces, and n is 1~7;
Reagent and condition in above-mentioned reaction equation: (a) the amino-alkane methyl esters of different chain length, O- benzotriazole-N, N, N ',
N '-tetramethylurea tetrafluoro boric acid, triethylamine, n,N-Dimethylformamide, room temperature, overnight;(b) hydroxylamine hydrochloride, potassium hydroxide, nothing
Water methanol, room temperature, 2h;(c) 3M NaOH, methanol, room temperature, 2h;(d) o-phenylenediamine, O- benzotriazole-N, N, N ', N '-four
Methylurea tetrafluoro boric acid, triethylamine, n,N-Dimethylformamide, room temperature, overnight;
The amino-alkane methyl esters of the different chain length is: glycine methyl ester, 3- aminopropanoate, 4-Aminobutanoicacid methyl esters,
5- aminopentanoic acid methyl ester, 6-aminocaprolc acid methyl esters, 7- aminoheptylic acid methyl esters or 8- aminocaprylic acid methyl esters;
(4) using p-nitrophenol as starting material, nucleophilic substitution occurs with the bromine alkanoic acid methyl esters of different chain length and obtains centre
Body 16a-16g, intermediate 16a-16g restore to obtain intermediate 17a-17g through Pd/C, and intermediate 17a-17g and 3 generation nucleophilics are anti-
Intermediate 18a-18g should be obtained, intermediate 18a-18g obtains final product 19a-19g through the ammonolysis reaction of ester;
Reaction equation is as follows:
Wherein n is 1~7;
Reagent and condition in above-mentioned reaction equation: (a) different chain length bromine alkanoic acid methyl esters, potassium carbonate, acetone flow back, overnight;(b)
Pd/C, methanol, hydrogen, room temperature, overnight;(c) isopropanol, concentrated hydrochloric acid flow back, overnight;(d) hydroxylamine hydrochloride, potassium hydroxide are anhydrous
Methanol, room temperature, 2h;
The bromine alkanoic acid methyl esters of the different chain length is: 2- methyl bromoacetate, 3- methyl bromide c, 4- bromo butyric acid methyl ester, 5- bromine
Methyl valerate, 6- bromocaproic acid methyl esters, 7- bromine methyl heptanoate or 8- bromine methyl caprylate;
(5) it is starting material with intermediate 3, nucleophilic substitution occurs with paranitroanilinum and obtains intermediate 20, intermediate 20
It is reduced to intermediate 21 through Pd/C, the docosandioic acid mono-methyl generation of intermediate 21 and different chain length is amide condensed to obtain intermediate
The ammonolysis reaction that ester occurs for 22a-22g, intermediate 22a-22g obtains final product 23a-23g;
Reaction equation is as follows:
Wherein n is 1~7;
Reagent and condition in above-mentioned reaction equation: (a) paranitroanilinum, isopropanol, concentrated hydrochloric acid flow back, overnight;(b) Pd/C, first
Alcohol, hydrogen, room temperature, overnight;(c) the docosandioic acid mono-methyl of different chain length, O- benzotriazole-N, N, N ', N '-tetramethylurea four
Fluoboric acid, triethylamine, N ' dinethylformamide, room temperature, overnight;(d) hydroxylamine hydrochloride, potassium hydroxide, anhydrous methanol, room temperature,
2h;
The docosandioic acid mono-methyl of the different chain length is: malonic acid monomethyl ester, monomethyl succinate, monomethyl glutarate, oneself
Acid monoethyl ester, pimelic acid mono-methyl, suberic acid mono-methyl or monomethyl azelate;
(6) using p-fluoronitrobenzene as starting material, occur during nucleophilic substitution obtains with the aminoalkyl methyl esters of different chain length
Mesosome 25a-25g, intermediate 25a-25g restore to obtain intermediate 26a-26g through Pd/C, and intermediate 26a-26g and intermediate 3 are sent out
Raw nucleophilic substitution obtains intermediate 27a-27g, and intermediate 27a-27g obtains intermediate 28a-28g through the ammonolysis reaction of ester;
Reaction equation is as follows:
Wherein n is 1~7;
Reagent and condition in above-mentioned reaction equation: (a) the aminoalkyl methyl esters of different chain length, potassium carbonate, N, N- dimethyl formyl
Amine, 50 DEG C, overnight;(b) Pd/C, hydrogen, methanol, overnight;(c) concentrated hydrochloric acid, isopropanol flow back, overnight;(d) hydroxylamine hydrochloride, hydrogen
Potassium oxide, anhydrous methanol, room temperature, 2h;
The amino-alkane methyl esters of the different chain length is: glycine methyl ester, 3- aminopropanoate, 4-Aminobutanoicacid methyl esters,
5- aminopentanoic acid methyl ester, 6-aminocaprolc acid methyl esters, 7- aminoheptylic acid methyl esters or 8- aminocaprylic acid methyl esters.
5. compound as claimed in claim 1,2 or 3 prevents or treats answering in the drug with tumor-related illness in preparation
With.
6. application as claimed in claim 5, which is characterized in that described and tumor-related illness are as follows: various blood tumors are each
Kind solid tumor.
7. application as claimed in claim 6, which is characterized in that all kinds of blood tumors are as follows: each quasi-leukemia, myelosis
Tumor;Each quasi-leukemia are as follows: serious acute lymphoblastic leukemia, acute myeloid leukaemia, acute megakaryoblastic are white
Blood disease;The myelosis tumor are as follows: chronic myelogenous leukemia, polycythemia vera, primary thrombocytosis, bone
Marrow fibrosis, chronic neutrophilic leukemia, chronic eosinophilic leukemia, systemic mastocytosis and other not
The myelosis tumor of classification.
8. application as claimed in claim 6, which is characterized in that the solid tumor are as follows: various forms of nasopharyngeal carcinoma, nephrocyte
Cancer, soft tissue sarcoma, thyroid papillary carcinoma, thymoma, liver cancer, breast cancer, melanoma, prostate cancer or retina are female thin
Born of the same parents' tumor.
9. it is a kind of suitable for pharmaceutical composition administered orally or parenterally, it include compound described in claim 1,2 or 3 and one
Kind or a variety of pharmaceutically acceptable carriers or excipient.
Priority Applications (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201710677980.2A CN107619407B (en) | 2017-08-10 | 2017-08-10 | Bis- target spot inhibitor of HDAC and VEGFR based on pazopanib structure and its preparation method and application |
PCT/CN2018/093968 WO2019029295A1 (en) | 2017-08-10 | 2018-07-02 | Pazopanib-based hdac and vegfr double-target inhibitor, preparation method therefor and application thereof |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201710677980.2A CN107619407B (en) | 2017-08-10 | 2017-08-10 | Bis- target spot inhibitor of HDAC and VEGFR based on pazopanib structure and its preparation method and application |
Publications (2)
Publication Number | Publication Date |
---|---|
CN107619407A CN107619407A (en) | 2018-01-23 |
CN107619407B true CN107619407B (en) | 2019-05-24 |
Family
ID=61088212
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201710677980.2A Expired - Fee Related CN107619407B (en) | 2017-08-10 | 2017-08-10 | Bis- target spot inhibitor of HDAC and VEGFR based on pazopanib structure and its preparation method and application |
Country Status (2)
Country | Link |
---|---|
CN (1) | CN107619407B (en) |
WO (1) | WO2019029295A1 (en) |
Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN1549813A (en) * | 2000-12-21 | 2004-11-24 | Pyrimidineamines as angiogenesis modulators | |
US20100291025A1 (en) * | 2009-04-13 | 2010-11-18 | Auspex Pharmaceuticals, Inc. | Indazole inhibitors of tyrosine kinase |
CN102060848A (en) * | 2010-12-09 | 2011-05-18 | 天津药物研究院 | Preparation and application of aromatic amine substituted pyrimidine derivatives |
CN103214467A (en) * | 2013-04-26 | 2013-07-24 | 中国人民解放军军事医学科学院微生物流行病研究所 | 5-[[4-[(2, 3-dimethyl-2H-indazole-6-yl) methylamino]-2-pyrimidyl] amino]-2-methyl-benzsulfamide derivative and preparation method and applications thereof |
Family Cites Families (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP1755394A4 (en) * | 2004-04-16 | 2009-08-05 | Smithkline Beecham Corp | Cancer treatment method |
CN103864764A (en) * | 2012-12-11 | 2014-06-18 | 齐鲁制药有限公司 | Indazole-substituted pyrimidinamine derivative, and preparation method and use thereof |
CN105524045B (en) * | 2014-10-22 | 2020-04-10 | 山东轩竹医药科技有限公司 | Tetracyclic anaplastic lymphoma kinase inhibitors |
-
2017
- 2017-08-10 CN CN201710677980.2A patent/CN107619407B/en not_active Expired - Fee Related
-
2018
- 2018-07-02 WO PCT/CN2018/093968 patent/WO2019029295A1/en active Application Filing
Patent Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN1549813A (en) * | 2000-12-21 | 2004-11-24 | Pyrimidineamines as angiogenesis modulators | |
US20100291025A1 (en) * | 2009-04-13 | 2010-11-18 | Auspex Pharmaceuticals, Inc. | Indazole inhibitors of tyrosine kinase |
CN102060848A (en) * | 2010-12-09 | 2011-05-18 | 天津药物研究院 | Preparation and application of aromatic amine substituted pyrimidine derivatives |
CN103214467A (en) * | 2013-04-26 | 2013-07-24 | 中国人民解放军军事医学科学院微生物流行病研究所 | 5-[[4-[(2, 3-dimethyl-2H-indazole-6-yl) methylamino]-2-pyrimidyl] amino]-2-methyl-benzsulfamide derivative and preparation method and applications thereof |
Also Published As
Publication number | Publication date |
---|---|
WO2019029295A1 (en) | 2019-02-14 |
CN107619407A (en) | 2018-01-23 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN112239469B (en) | Targeted protein degradation c-Met degradation agent and preparation method and application thereof | |
KR102366670B1 (en) | O-aminoheteroaryl alkynyl-containing compound, preparation method therefor, and use thereof | |
Zhang et al. | Design and discovery of 4-anilinoquinazoline-urea derivatives as dual TK inhibitors of EGFR and VEGFR-2 | |
CN103068384B (en) | Cyclopropyl dicarboxamides and analogs exhibiting anti-cancer and anti-proliferative activities | |
CN108864057A (en) | Bis- target spot inhibitor of JAK and HDAC containing 4- amino-pyrazol structure and its preparation method and application | |
CN104341425A (en) | Deuterated acetylenic derivative, pharmaceutical composition and application thereof | |
JP6630844B2 (en) | 5-membered heterocyclic amide WNT pathway inhibitor | |
WO2016023217A1 (en) | Quinazoline derivative, preparation method therefor, and pharmaceutical composition and application thereof | |
CN107151240A (en) | Polysubstituted carbostyril compound of one class and its production and use | |
CN105218532A (en) | Benzotriazole compounds, preparation method and its medicinal use | |
EP3181554B1 (en) | Quinazoline derivative | |
WO2023016543A1 (en) | Urea multi-target tyrosine kinase inhibitor and multiple medical applications thereof | |
CN113480543A (en) | 2,6, 8-polysubstituted imidazo [1,2-a ] pyrazine and synthetic method and application thereof | |
KR101789934B1 (en) | Novel compound having tumor diagnosis or tumor growth inhibitory activity on EGFR mutant and medical uses comprising the same | |
CN107619407B (en) | Bis- target spot inhibitor of HDAC and VEGFR based on pazopanib structure and its preparation method and application | |
CN102775381B (en) | Substituted hydrazide compound, and its preparation method, medicinal compositions and application | |
JP2016539993A (en) | N-substituted pyrazolylguanidine F1F0-ATPase inhibitor and therapeutic use thereof | |
CN103664876B (en) | Quinoline derivatives and uses thereof | |
CN114315795B (en) | 68 Ga-marked inhibitor radioactive probe for targeting fibroblast activation protein and preparation method thereof | |
JP7092356B2 (en) | Biarylurea derivatives or salts thereof, and their preparation methods and uses | |
CN105924403A (en) | Cyclomalonamide compound with antitumor activity, and preparation method and application thereof | |
CN107501283B (en) | Preparation of substituted arylmethyl hetero-substituted anilino ethylene glycol ether cycloquinazoline and application of tumor treatment drug | |
CN104447733B (en) | 1-benzyl-2-pyrrolinone-4-amides compound and preparation method and application | |
WO2017097215A1 (en) | Wnt pathway inhibitor embedded with ureas structure | |
CN106187919A (en) | Quinazoline derivant containing hydroxamic acid side chain and preparation and application |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
GR01 | Patent grant | ||
GR01 | Patent grant | ||
CF01 | Termination of patent right due to non-payment of annual fee | ||
CF01 | Termination of patent right due to non-payment of annual fee |
Granted publication date: 20190524 |